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ABSTRACT
The use of radiation is broad in biological systems, in different areas of research
mostly in health.
Radiation is used to kill cancer. In radiation therapy proper calculation is done so that
a maximum dose is delivered to the cancer . Inspite of this precaution, radiation
effects healthy tissue. This effect is especially dangerous when the tumor is located
near important organs. Thus in radiation therapy, it is important to reduce the dose
and the damage to the healthy tissues and organs. The damage on the healthy tissues
due to radiation therapy in cancer could be reduced by reducing the radiation dose to
get the same treatment effect or by enhancing the radiation. The enhancement of
radiation effect in vitro and in vivo can be obtained by targeted drug delivery on the
cancer. Also photo dynamic therapy can be supplemented by the use of radiation
therapy on the cancer by targeted drug delivery.
Another use is the development of a bio dosimeter. In a large scale nuclear event it is
important to measure the radiation dose exposed to humans. Also it is likely that the
people who are exposed to radiation are not wearing the dosimeter. So a method of
estimating radiation dose to a person exposed to radiation

without a physical

dosimeter would be a very useful procedure. One possible method is the use of gene
expression analysis, which is based on the fact that the expression of the genes will
change due to the absorbed radiation. So developing a biological dosimeter based on
the gene expression analysis could quantify the radiation dose given to the patients
during radiation therapy or to assess the risk of cancer developing in the general
population. This biological dosimeter could even be used when the physical

dosimeters are insufficient to estimate the risk caused by the radiation exposure or
even years after being exposed to nuclear accidents.
The main goal of the work presented here is to investigate the following topics
-

Use of gold pHLIP to enhance the radiation effect in cancer cells

-

Review on the in vivo research done to enhance radiation using gold
nanoparticles

-

Analyze the gene expression results from irradiated drosophila melanogaster to
develop a biological dosimeter.

-

Use of X-ray to activate targeted Copper Cysteamine nanoparticles
photosensitizer to reduce tumor size in mice.

A review work I have done on the researches related to enhancement of radiation
using gold nanoparticles in tumor bearing mice showed that the targeted nanoparticles
are a promising method for achieving radiation enhancement due to their shape, size ,
surface chemistry and the properties of the nanoparticles..
Gold nanoparticles are susceptible to X-rays compared to tissues and release extra
electrons by Auger effect when the tumor treated with gold is irradiated. These auger
electrons have low energy and are localized within the tumor site killing the cancer
cells. However tumor targeting peptide pHLIP (pH Low Insertion Peptide) conjugated
to gold nanoparticle specifically targets low pH medium (tumor) which when
irradiated reduces the risk of killing healthy tissues near by and increases the uptake of
the particles in the cancer mostly in the cellular membranes compared to only gold.
The experimental results on cellular uptake of gold showed that there was an
enhancement of gold uptake by 52% at low pH compared to normal pH ( P value =

.008)and also in targeted gold by 34% compared to non targeted gold at low pH (P
value= .023). The images obtained by distribution of gold experiment showed that the
cellular uptake of gold-pHLIP is higher compared to gold alone . The targeting of
plasma membrane by gold-pHLIP is seen clearly on all the images and some staining
of internal organelles and nuclei membranes as well. The clonogenic

assay

experiment at 1.5Gray radiation showed a statistically significant 24% decrease in
survival for cells treated with gold-pHLIP at low pH compared with cells treated with
no gold. Also a statistically significant 21% decrease in survival for cells treated with
gold-pHLIP at low pH compared with cells treated with gold alone. Thus Gold
nanoparticles conjugated with pHLIP significantly increases the amount of gold
particles in cancer cells thus enhancing the radiation effect and increasing the amount
of cancer cell death from radiation.
Copper cysteamine nanoparticles placed in the tumor site release cytotoxic singlet
oxygen molecules on irradiation. The Cu-Cy nanoparticles being photosensitizers kill
tumor when activated by radiation. Photosensitizers are limited to shallow tumors.
Here we use X-radiation to photosensitize the pHLIP targeted Cu-Cy nanoparticles to
kill even the deeply seated tumors in vivo. The results from the in vivo experiment we
have done shows significant tumor destruction under X-ray activation. ANOVA
analysis showed that the mice treated with targeted particles had a significantly
different tumor sizes than mice treated with no particles, as well as mice treated with
non-targeted particles. Also the use of targeted copper cysteamine nanoparticles
affected the survival time after irradiation, compared to irradiation using no particles
on mice. This work confirms the effectiveness of Copper Cysteamine nanoparticles,

targeted to tumors, as a photosensitizer when activated by radiation therapy. Thus the
aid of radiation therapy to photodynamic therapy by the use of tumor targeted CuCy
nanoparticles efficiently does tumor destruction shrinkage with the increase in mice
survival.
Gene expression analysis on a published data showed that the expression of genes are
radiation dose dependent and some genes behaving predictably as a function of
radiation dose at different time points after radiation can be used as a bio dosimeter.
The data analysis showed that 6 genes from drosophila melanogaster show linear
response (R2 > 0.9) with radiation dose at all time points after irradiation. Four of
these genes have human homologues. Dropping off the lowest radiation dose (10
roentgen being very low for the fruit flies), 13 genes show a linear response with dose
at all time points including 5 of 6 genes in whole data set. Of these 13 genes, 4 have
human homologues and 8 have known functions. The Irbp (inverted repeat – binding
protein) gene among the above is very important as it is a DNA repair gene. It is
reasonable to predict that DNA damage is linear with radiation dose; thus, it is logical
that some DNA repair genes may respond linearly in expression. Irbp has homologues
in organisms that are as complex as humans and chimpanzees and in organisms as
Japanese rice . The expression of this panel of gene, particularly those with human
homologues, could potentially be used as the biological indicator of radiation exposure
in dosimeter applications.
Thus we could use radiation to kill tumors more effectively or the development of a
biological dosimeter could help people to estimate the risk of cancer caused due to
their exposure to radiation.
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PREFACE
This dissertation is written in the ‘Manuscript Format’ using the Thesis/ Dissertation
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into a chapter. Tables and figures of each manuscript are listed under the
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radiation

effect

on

cancer

cells

by

gold-
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2.
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2016. Gold nanoparticles for radiation enhancement in vivo. Jacobs journal of
radiation oncology, 3(1).

3.

Shrestha, S., Vanasse, A., Cooper, L.N. and Antosh, M.P., 2017. Gene
Expression as a Dosimeter in Irradiated Drosophila melanogaster. Journal of
Computational Biology, 24(12), pp.1265-1274.
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Abstract
Previous research has shown that gold nanoparticles can increase the effectiveness of
radiation on cancer cells. Improved radiation effectiveness would allow lower
radiation doses given to patients, reducing side effects; alternatively, it would provide
more cancer killing at current radiation doses. Damage from radiation and gold
nanoparticles depends in part on the Auger Effect, which is very localized; thus, it is
important to place the gold nanoparticles on or in the cancer cells. In this work, we use
the pH-sensitive, tumor-targeting agent, pH Low Insertion Peptide (pHLIP), to tether
1.4 nm gold nanoparticles to cancer cells. We find that the conjugation of pHLIP to
gold nanoparticles increases gold uptake in cells compared to gold nanoparticles
without pHLIP, with the nanoparticles distributed mostly on the cellular membranes.
We further find that gold nanoparticles conjugated to pHLIP produce a statistically
significant decrease in cell survival with radiation, compared to cells without gold
nanoparticles as well as to cells with gold alone. In the context of our previous
findings demonstrating efficient pHLIP-mediated delivery of gold-nanoparticles to
tumors, the obtained results serve as a foundation for further pre-clinical evaluation of
dose enhancement.

Keywords: Tumor, acidity, targeting, gold nanoparticles, radiation
Statement of Significance

Nanometer-sized gold particles are shown to increase the effectiveness of radiation in
killing cancer cells. Improved radiation effectiveness allows less radiation to be used,
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reducing side effects to patients. Alternatively, more cancer killing could be had for
current radiation doses. Here we used pH Low Insertion Peptide (pHLIP) to tether
gold nanoparticles to membranes of cancer cells. This increases their effectiveness
because the radiation/particle effect is very localized. We find that pHLIP significantly
increases the amount of gold particles in cancer cells, as well as the amount of cancer
cell death from radiation. This methodology is promising for clinical research, as
previous results show efficient targeting of gold nanoparticles to tumors by pHLIP.

Introduction
Gold is an inert and generally non-toxic material with unique properties suitable for
many applications such as cancer diagnosis and treatment (1-7). Nanometer-size gold
particles have recently been shown to increase radiation damage to tumors (2,8-11).
With enhanced radiation, the same level of tumor killing can be had with less radiation
to a patient, reducing side effects of radiation treatments. Similarly, more tumor killing
can be had for the levels of radiation that are currently given.
The increase in radiation effectiveness with gold nanoparticles is due largely to two
causes. First, gold is capable of absorbing radiation at a significantly higher rate than
tissue, up to about 100 times more for keV energies (2). Second, gold nanoparticles
that interact with radiation can release extra electrons via the Auger Effect. The Auger
Effect occurs when an atom releases electrons post-ionization. Multiple electrons,
called Auger electrons, can be released per ionization. The Auger electrons usually
have low enough energy so that their effect is localized to the area surrounding the
gold nanoparticles; see for example figure 1 in ref.11. Thus, it is very important to
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effectively deliver gold nanoparticles to cancer cells in tumors and locate them near
DNA or other vital cellular structures and components.

Specific delivery can be accomplished by conjugating gold (or other nanoparticles) to
antibodies or ligands that target overexpressed proteins on cancer cell surfaces; this
approach has been actively explored for many years for delivery of small molecules.
However, several recent studies have raised serious questions about the efficacy of
targeting ligands on the nanoparticle accumulation in tumor tissues. Multiple reports
have shown that targeted nanoparticles did not lead to increased tumor accumulation
over non-targeted controls, although increased cellular uptake was observed in each
case (12-14). In addition, histological studies showed that antibodies conjugated with
gold nanoparticles do not penetrate deeply into tumors, but mostly stain peripheral
tumor regions (15). The direct injection of micron-sized gold particles does not lead to
tumor targeting, as particles stayed only at the injection site and were not able to
diffuse even within a tumor, hindering tumor coverage (16).
Our approach is based on targeting of tumor acidity, which correlates with tumor
malignancy (17-19). The pH-sensitive targeting agents we are developing are based on
the action of a family of pHLIPs (pH Low Insertion Peptides), which can “sense”
acidity at the surface of cancer cells and deliver diagnostic and therapeutic molecules
to tumors of different origins (20-25). It was shown that pHLIP can promote fusion of
liposomes with cancer cells and cellular delivery of various payloads (26, 27)
including small gold nanoparticles (26). Recently, pHLIP was successfully employed
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for the targeting of various nanoparticles to tumors and other acidic diseased tissue
(28-31).
pHLIP has also been used to mediate pH-controlled delivery of both 13 nm water
soluble gold nanoparticles coated with luminescent europium into human platelets in
vitro (32), and

1.4 nm gold nanoparticles to tumors (33). Intratumoral and i.v

administrations of both demonstrated a significant enhancement of tumor uptake of
1.4 nm gold nanoparticles conjugated with pHLIP. Statistically significant reduction
of gold accumulation was observed in acidic tumors and kidney when pH-nonsensitive
K-pHLIP was used as a vehicle, suggesting an important role of pH in the pHLIPmediated targeting of gold nanoparticles.
In this work, we made another important step toward clinical application of 1.4 nm
gold nanoparticles conjugated with pHLIP. We show that pHLIP can deliver gold to
cellular components in a pH-dependent manner and enhance the radiation damage in
cells.

Results
In this work we used 1.4 nm diameter gold clusters functionalized with maleimide.
Maleimide-gold clusters were conjugated with WT-pHLIP containing a single Cys
residue at the N-terminus:
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADET
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After conjugation, the construct was purified, lyophilized, redissolved in DMSO,
quantified and used in experiments with cells. As a control (gold alone) we used nonfunctionalized 1.4 nm gold clusters.

Cellular Uptake and Distribution of Gold
We investigated uptake of gold nanoparticles at normal and low pHs (pH 7.4 and 6.0,
respectively), with and without pHLIP on human lung carcinoma (A549 cells). At pH
6.0 pHLIP was found to increase cellular uptake of gold nanoparticles by 34%
compared to gold nanoparticles alone (p value 0.023) (Fig.1 and SI Appendix, Table
S1). The uptake of pHLIP-gold at pH 6.0 increased by 53% compared to the uptake at
pH 7.4 (p value 0.008). The uptake of gold alone was also enhanced at pH 6.0
compared with pH 7.4 (P value = 0.014). The uptake of gold-pHLIP was ~60% of the
treated dose (1.8µg), which was about 1.1µg gold. Because each treatment had ~1
million cells, the amount of gold per cell was ~ 1.1X10-6 µg. We expect that uptake of
pHLIP-gold at normal pH by noncancerous cells will be much lower, since pH at the
surface of glycolytic cancer cells is about 6.6-6.8 even when bulk pH of media is 7.4
(unpublished data). The uptake of gold alone was also enhanced at pH 6.0 compared
to pH 7.4 (p value 0.014).
Light microscopy was used to establish the distribution of gold nanoparticles in cells.
Bright field images of cells treated with gold-pHLIP or gold alone and enhanced with
silver are shown in Figure 2. The cellular uptake of gold-pHLIP is higher compared to
the uptake of gold alone (Figure 2A and -B; the images are taken using 20x objective).
The representative bright field image of cell treated with gold-pHLIP and enhanced
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with silver obtained at high magnification is shown in figure 2C (the image is taken
using 100x objective). The overlay of fluorescent images of nuclear stained with DAPI
(blue) and cellular membrane stained with HQ silver deposited on the goldnanoparticles (red) are shown in figure 2D. The targeting of the plasma membrane by
gold-pHLIP is clearly seen on all images. We also observed some staining of internal
organels and nuclei membranes. Targeting of mitochondria and nuclear membranes
was observed in experiments with pHLIP-coated liposomes containing lipids
conjugated with fluorescent dyes and gold nanoparticles (27).

Clonogenic Assay
Clonogenic assay experiments were performed to assess cell survival after treatment
of cells with gold or gold-pHLIP and radiation of treated and non-treated cells. The
results of the experiments are summarized in figure 3 and SI Appendix, Tables S2-S5.
We tested 0, 1.5 and 3 Gray of radiation. Gold nanopoarticles alone or conjugated with
pHLIP were not toxic for cells in the absence of radiation. For 1.5 Gray of radiation,
we observed a statistically significant 24% decrease in survival for cells treated with
gold-pHLIP at low pH, as compared to cells treated with no gold. We also observed a
statistically significant 21% decrease in survival for cells treated with gold-pHLIP at
low pH as compared to cells treated with gold alone. The effect of gold was not
significant at 3 Gray of radiation, likely because the survival of cells at 3 Gray was
low.
Two different methodologies were used: excess of gold or gold-pHLIP was removed
after treatment with cells before radiation, or excess of gold and gold-pHLIP was not

7

removed (non-removal corresponds with the values shown in red in SI Appendix,
Tables S2-S5). The clonogenic assay results in Fig. 3A include data obtained at both
different methodologies. Fig. 3B shows the data obtained in the experiments when
gold constructs were not removed before radiation. Surprisingly, overall the nonremoval data have better survival than the removal data; perhaps this is a result of the
removal process stressing the cells.
We assessed statistical significance for data obtained at 1.5 Gray of radiation by
performing an analysis of variance (ANOVA), summarized in Table 1 and SI
Appendix, Table S6. When determining the p values between different gold
treatments, we accounted for the difference in methodology as an additional variable
in the analysis of variance (see Methods section for more details). Our data clearly
indicate that cell treatment with gold-pHLIP results in a statistically significant
decrease in cell survival as compared to a treatment with no gold (p value 3.610-5) or
gold alone (p value = 0.015).
In a separate experiment, cells were treated with gold constructs at pH 7.4, where
pHLIP is less effective at inserting into the cellular membranes. Only small and
statistically insignificant differences in survival between non-treated and treated cells
were seen; the data is given in SI Appendix, Tables S2, S3, and S5.

Discussion
The treatment of cancer involves a trade-off between killing all cancer cells and
impacting healthy tissue and organs as little as possible. To reduce side effects and
enhance lethal effects of radiation for cancer cells the approaches of binary therapy
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were introduced. Binary radiation therapy targets cells at the biological level with a
noncytotoxic agent that is “activated” by low energy radiation, thereby destroying
cancer cells wherever they may reside, while sparing normal cells in proximity to the
diseased cells. A number of binary radiation therapies have been and are being
explored (9, 34-36) one of the more promising approaches is based on dose
enhancement through Auger electron emission secondary to the photoelectric effect
dominant at low photon energies. Auger electron emission generates a cascade of lowenergy electrons that travel very short distances and deposit their energy locally. The
number of Auger electrons generated in targeted cells can be increased significantly
by introducing material of a high atomic number (high-Z) into the target as long as the
radiation energy is at or near the K, L, or M electron shell binding energies for the
material. High-Z nanoparticles made of iodine, gadolinium, or gold are predicted to
produce a clinically achievable dose enhancement of as much as 10 fold. Because low
energy electrons travel very short distances, it is crucial to deliver and accumulate
high-Z material on or in cancer cells in tumors.
Our strategy is to deliver gold, which is an inert, high-Z material widely used in
medicine, to cancer cells for enhancement of radiation effects. The delivery approach
we propose is based on the energy of membrane-associated folding of peptides from
the pHLIP family to target cellular membranes in a pH-dependent manner (22, 24, 37).
At pH <7.0 pHLIPs insert into the lipid bilayer of the membrane, which is
accompanied by a coil-helix transition and formation of a transmembrane helix. It has
been shown that pHLIP delivery agents can target acidic tumors with high accuracy
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and deliver nanoparticles, including gold, to cancer cells in tumors (33). In this work,
we show the effect of gold-pHLIP on radiation-induced cell death.
The dose enhancement depends strongly on the photon energies used for irradiation, as
well as on the location and the size of gold nanoparticles. Regarding the photon
energy, the ratio of gold absorption to human absorption is highest between ~10 and
100keV, with the ratio reaching approximately as high as 100 (2). We used 250 kVp
X-rays with Sn-Thoraeus filtering to use the high relative absorption by gold while
also accounting for the fact that lower-energy photons will be absorbed at too small of
a depth to be useful. Regarding the location, it is very important to deliver gold
nanoparticles as close as possible to cancer cells, as the dose deposited by Auger
electrons increases as distance from the gold nanoparticles decreases(11). We used
pHLIP to locate the gold nanoparticles to cancer cells. Regarding the nanoparticle
size, it is best to use as small a gold nanoparticle size as possible to minimize the
energy deposited inside the gold by Auger electrons. Simulations by McMahon et al.
(11) predict an increase in relative biological effectiveness for decreasing sizes of gold
nanoparticles. We used 1.4-nm –diameter gold nanoparticles.
The results of our present study indicate that pHLIP causes cells to take up more 1.4nm gold nanoparticles than cells without pHLIP. The gold nanoparticles deposited by
pHLIP mostly accumulate on the plasma membrane. As a result, gold nanoparticles
delivered to cells by pHLIP can enhance radiation-induced decreases in cell survival.
Gold nanoparticles tethered to the lipid bilayer of the plasma membrane by pHLIP
may trigger cell death by inducing oxidation of lipids, cholesterol and membrane
proteins. The oxidized lipids are known to modify membrane physical properties, such
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as thickness, permeability, level of hydration and polarity, lipid transbilayer diffusion,
loss of lipid asymmetry and phase segregation, which results in apoptosis (38, 39).
The exposure of phosphatidylserine lipids to the outer leaflet of the lipid bilayer,
promoted by lipid oxidation, serves as a recognition signal for macrophages to
phagocytose the apoptotic cell (40).
The combination of the clonogenic and uptake results suggests that pHLIP is able to
enhance radiation-induced death by targeting cancer cells and increasing gold uptake.
This is particularly important for future pre-clinical testing. Experiments on cultured
cells reflect steady-state conditions, when constructs are exposed to cancer cells
during the time of incubation. However, in vivo studies reflect kinetic conditions,
when blood flow is high and constructs have limited time to reach cancer cells and
accumulate there. Our previous in vivo studies indicate that pHLIP targeting of 1.4 nm
gold nanoparticles to tumors was 11 and 6 times higher compared to tumor targeting
by gold alone (when administrated intratumorally and intravenously, respectively)
(33).

Thus, in an upcoming experiment on mice, we expect to observe more

significant enhancement of radiation-induced cancer killing in mice compared to data
obtained on cells. This might open a new avenue for the treatment of acidic, highly
metastatic tumors in humans.

Methods
Materials: Materials include nonfuctionalized (from Nanoprobes), monomaleimido
nanogold (from Nanoprobes), Cys-pHLIP (synthesized and purified by CS Bio), Tris(2-carboxyethyl) phosphine, hydrochloride (from Life Technologies), Dulbecco’s
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Modified Eagle’s Medium (from Sigma Aldrich), gluteraldehyde [25%(wt/wt) in
water; from Sigma Aldrich], crystal violet (from Sigma Aldrich), Synaptophysin (from
Molecular Probes by Life Technologies), DAPI (from Sigma Aldrich) and silver
enhancement reagent (from Nanoprobes). Cell type was human lung carcinoma A549
cells (from American Type Culture Collection).

Preparation of Gold (Gold Alone), Gold conjugated to pHLIP (Gold-pHLIP):
Gold nanoparticles were cluster gold, 1.4 nm diameter, from Nanoprobes, Inc.
Monomaleimido nanogold was conjugated to Cys-pHLIP in 40 mM phosphate buffer
containing 300 mM NaCl at pH 6.5. A reducing agent, Tris-(2-carboxyethyl)
phosphine, was added into the reaction mixture (10x excess compared to pHLIP) to
reduce pHLIP-S-S-pHLIP dimers and promote reaction with gold-malemide . The
reaction vial was incubated overnight at room temperature on shaker. The next day,
the gold-pHLIP conjugates were purified using Amicon Ultra (10K) centrifugal filters
according to company recommended protocol. The product was then lyophilized,
redissolved in DMSO. The concentration of peptide and nanogold was determined by
absorbance at 280 nm ( =13,940 M−1 cm−1) and 420 nm ( =155,000 M−1 cm−1),
respectively Nonfunctionalized gold (gold alone) was dissolved in DMSO and
quantified using absorbance of gold at 420 nm.

Cellular Uptake of Gold: Approximately 1 million cells A549 were treated with 0.3
µM of either gold Alone or gold-pHLIP in cell suspension in serum free DMEM at pH
6.0 and 7.4 for 1 hour. One nanogold particle(1.4nm in diameter) contains, on average,
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60 gold atoms, and 0.3uM particles in 0.5mL solution correspond to 1.8µg of gold.
After 1 hour of treatment, the cells were pelleted using centrifugation (2,000 rpm x g
for 5 min) followed by removal of treatment and washing cells with PBS three times.
The cells were then dissolved in concentrated nitric acid followed by sonication for
about 2 hours. Concentrated solution samples were diluted to give 2%(wt/vol) nitric
acid and analyzed via inductively coupled plasma mass spectroscopy (ThermoScientific x7 series) against calibration standards (IMS 103; UltraScientific).

Cellular Distribution of Gold: About 20,000 A549 cells were seeded on collagen
coated glass bottom dishes (MatTek) in 200 µl volume. The next day, cells were
treated for 1 hour with gold and gold-pHLIP at 0.5 µM concentration at pH 6.0 in
DMEM with no FBS. After treatment, the cells were washed 3 times with PBS
followed by fixation in 4% formaldehyde for 20 min. The cells were permeabalized
with 0.3% Triton X100 for 5 min, followed by washing with PBS and deionized
water. Next, the cells were developed with freshly prepared HQ Silver reagent
(Nanoprobes) for about 20 min, followed by washing with deionized water. Finally the
cells were stained with 5 µM DAPI in PBS for 5 min, followed by washing with
deionized water. The cells were imaged using light microscope in bright field regime
to visualize gold enhanced by silver, and in the fluorescent regime to monitor DAPI
and silver fluorescence using cut off filters (ex:em 360 nm/460 nm andex:em 542
nm/620 nm, respectively).
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Irradiation of Cells: Irradiation was done using a Philips RT 250 X-ray machine, at
settings of 250 kVp and 15 mA. A 0.4 mm Sn-Thoraeus Filter was used. The halfvalue thickness for this setup is listed as 2.8mm Cu. The dose rate was ~ 1.5
Gray/minute for each irradiation. Calibration readings were performed before each
measurement using a Radcal 2026C dosimeter, and the reading was corrected for
differences in temperature and pressure from standard temperature and pressure. The
irradiation dose varied by ~ 7% between the center of the cell dish and the rightmost
well in the irradiation plate that we used (there was ~ 1-2% variation in the leftmost
well); the rightmost well was only used in experiments 7-11 and there were always at
least 3 wells used per treatment.

Clonogenic Assay: The day before irradiation, 25,000 A549 cells per well were
seeded in 48-well plates the day before irradiation. One plate with different treatment
conditions was used for each radiation dose. The next day, the cells were treated with
no gold, gold alone or gold-pHLIP at 8 µM concentration in 300 µl DMEM with no
FBS at pH 6.0 for 3h. In experiment 11, the medium pH during treatment was 7.4
instead of 6.0. In one set of experiments, the excess of gold was removed and 500 µl
of fresh DMEM medium of pH 7.4 with 10% FBS was added. In the other set of
experiments the excess of gold was not removed, then 200 µl of fresh DMEM medium
of pH 7.4 with 25% serum was added into wells to have 10% of FBS in final volume
in the well. The treatment period was ~ 3 h.
Cells were irradiated as described in the irradiation methods; control cells
accompanied the irradiated cells to and from the x-ray machine. Irradiated cells were
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dissociated and combined for each treatment type, counted (using a Coulter Counter
Z1 instrument from Beckman Coulter for experiments 1-11 and an Auto T4 instrument
from Nexcelom Bioscience for experiments 12-17) and then reseeded in a 6-well plate.
Two hundred cells per well were seeded for 0- and 1.5- Gray radiation doses and 500
cells per well were seeded for 3- Gray radiation dose. In generally, six wells were
seeded per treatment type; the number of entries in SI Appendix, Table S2 is the
number of wells. A table entry with 12 values represents a treatment that was done
twice in the same experiment, with the results combined. After ~ 10 days, each well
was fixed and stained using a 2- mL mixture of 4% glutaraldehyde and 0.5% crystal
violet in distilled water. Stained cell colonies were hand-counted under a microscope.
A colony was defined as a distinct group of cells that contained 50 or more cells.

Analysis of Cellular Uptake Data: The values in SI Appendix, Table S1 are six
readings from a mass spectrometer. P values for statistical significance were computed
using the t test, because the between-reading variance was much greater than the error
in each reading.

Analysis of Clonogenic Assay Data: To calculate statistical significance, the data
summarized in SI Appendix, Tables S2-S5 were analyzed using an ANOVA, followed
by a post hoc test using Tukey’s Honest Significant Difference. Each individual
measurement from the clonogenic assay dish was treated as a biological replicate, and
normalized to the average of the “0 Radiation, No Gold” measurements from the same
experiment.
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The linear model fitted for the ANOVA had three variables: normalized survival
(dependent variable), gold treatment (independent variable) and removal/non-removal
of excess gold (independent variable). We left the data for 0 Radiation out of the
analysis because normalizing by the “0 Radiation, No Gold” data points introduces a
correlation if we use the data by which we are normalizing. We analyzed the data for
1.5 Gray and 3 Gray separately because we were only really interested in the effect at
1.5 Gray.
In the 1.5 Gray data, the interaction term between gold treatment and removal/nonremoval was significant. This is consistent with the gold treatments having different
effectiveness depending on whether or not the excess gold was removed.
We also did one experiment at high pH, as mentioned in the results section. This was
analyzed with a separate analysis of variance. The data are included as experiment 11
in SI Appendix, Tables S2. S3, and S5.

In Fig. 3, error shown is the SEM (41). SE was calculated using R, as SD divided by
square root of the number of samples. In checking the procedure for this calculation,
we used StatPlus, version v5 (AnalystSoft Inc.).
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Tables
Table 1. Summary of ANOVA results for 1.5 Gray radiation. Detailed results are in SI
Appendix, Table S6.

Model
Normalized Survival=Treatment+Removal+(TreatmentRemoval)
P Values
3.6410-5

No Gold vs. Gold pHLIP
Gold pHLIP vs. Gold Alone

0.015

No Gold vs. Gold Alone

0.832
5.9510-6

Removal vs. Non-Removal
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Figures

Figure 1. Cellular uptake of gold. Values are averaged from normalized readings on a
mass spectrometer, as detailed in Methods. All measurements are given in SI
Appendix, Table S1. Data are normalized to gold Alone at pH 7.4.
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Figure 2. Gold distribution in cells. The bright field (A-C) and fluorescence (D)
images of cells treated with gold (A) and gold-pHLIP (B-D), followed by washing,
fixation and enhancement with HQ silver, are shown at different magnifications (the
bar on each image shows 10 µm- scale). The overlay of fluorescent images of nuclear
stained with DAPI (blue) and cellular membrane stained with HQ silver (red) are
shown on D.
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Figure 3: Average cell survival after radiation and treatment (or no treatment, control)
with gold or gold-pHLIP at pH 6.0. The data shown in A are from the experiments
with either removal or non-removal of excess gold before radiation. The data shown in
B are only from the experiments with non-removal of excess gold before radiation.
Error shown is SEM.
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Supplementary Information (SI) Appendix

Table S1. Cellular uptake of gold-pHLIP and gold. The mean and standard
deviation of these data points are presented in figure 1, and the calculation of
statistical significance is described in the methods section. Data are normalized so that
Gold Alone, pH 7.4 has a mean of 1.

Gold-pHLIP, pH 6.0

1.602±0.038, 1.538±0.013, 2.441±0.012, 2.006±0.006, 2.012±0.006,
2.023±0.000

Gold-pHLIP, pH7.4

0.838±0.006, 0.901±0.010, 1.525±0.006, 1.246±0.003, 1.826±0.004,
1.246±0.006

Gold Alone, pH 6.0

1.023±0.005, 1.122±0.006, 1.733±0.004, 1.687±0.005, 1.542±0.004,
1.577±0.006

Gold Alone, pH 7.4

1.004±0.008, 0.996±0.005, 1.339±0.004, 1.032±0.006, 0.835±0.012,
0.794±0.002
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Table S2. Clonogenic Assay Colony Counts. For 0 and 1.5 Gray radiation, 200 cells
were seeded; 500 cells were seeded for 3 Gray radiation. Treatment for experiments 110 and 12-17 were done at pH 6.0; experiment 11 was done at pH 7.4. The values
shown in red were obtained in the experiments where excess of gold constructs was
not removed before radiation; the other data were obtained in the experiments where
the excess gold was removed before radiation. The input for the analysis of variance
(detailed in the methods section) was the values from this table, divided by the mean
of the “0 Radiation, No Gold” values for its corresponding experiment.
Exp.1

Exp.2

Exp.3 Exp.4 Exp.5 Exp.6 Exp.7

32,24,2
5,32,32
0 Radiation, 102,98,
,31,35,
No Gold
99
28,32,3
6,35,33

69,76,8
9,83,73
,90,82,
72,77,8
5,64,86

0 Radiation,
Gold Alone

81,66,9
6,70,47
,88

Exp.8

Exp.9 Exp.10 Exp.11 Exp.12 Exp.13

54,35,
48,47,6
44,49,
59,54, 60,49, 55,54,4 54,47,5 39,39,4 3,64,58
42,47,
51,73, 43,62, 8,43,48 5,59,57 6,47,33, ,73,57,
55,59,
65,65 55,70
,57
,52
45, 33,63,7
40,58,
1,62,57
54,48

74,50,
67,57,
70,72,
72,69,
77,69,
63,82

24,26,4 71,53,5 63,51,
5,34,23, 6,66,54 66,48,
36
,55
49,56

1.5 Gray
Radiation,
No Gold

12,16,1
1,18,15 33,45,4 27,21, 46,37,
80,58,
,13,14, 5,28,34 26,20, 43,31,
59
14,16,1 ,40
16,27 28,46
9,15,22

1.5 Gray
Radiation,
Gold Alone

56,31,3
6,56,33
,29

46,25,3 26,23,2 23,32,2 59,46,5 50,37,
0,32,32 1,31,19 5,24,21, 6,62,36 38,61,
,18
,31
27
,53
44,51

30,16,2 37,39,4 57,37,
4,18,12, 1,31,30 41,49,
24
,49
34,49

34,20, 27,27, 16,17,1 23,22,2 16,15,1 36,28,3 41,34,
28,43, 36,25, 7,21,12 0,30,15 6,18,10, 9,29,20 39,45,
28,26 23,29
,18
,22
13
,44
44,48

27,17,3
1,25,22
3 Gray
44,26,3 43,27, 59,57, 29,25, 52,45,5 27,21,2 33,25,2 61,44,7 60,53,
104,99, ,34,21,
Radiation,
7,54,35 36,39, 54,62, 27,28, 5,44,42 4,35,31 9,34,21, 2,50,66 60,67,
85
7,
No Gold
,52
24,26 43,53 31,35
,56
,27
33
,73
53,55
21,39,2
2,14
3 Gray
Radiation,
Gold Alone

3 Gray
Radiation,
Gold-pHLIP

44,24,4
2,39,41
,26

Exp.15

Exp.16

Exp.17

62, 61,
54, 64,
57,
61,59,
56, 60,
50, 43,
53

42, 40,
52, 59,
40,
49,33,
47, 37,
43, 38,
47

39, 45,
49, 41,
37,
48,48,
52, 50,
57, 49,
49

65, 49,
44, 55,
46,
42,37,
43, 39,
34, 33,
34

57, 54,
50, 54,
64,
49,37,
32, 42,
37, 47,
42

45, 57,
43, 40,
41, 38

53, 62,
58, 65,
53, 55

44, 44,
38, 32,
42, 46

42, 50,
41, 42,
51, 44

56, 63,
41, 50,
48, 48

49, 65,
44, 41,
50, 51

47,37,4 59,53,6 67,49,
8,30,42, 9,71,56 53,68,
44
,65
56,65

0 Radiation,
Gold pHLIP

1.5 Gray
Radiation,
Gold-pHLIP

Exp.14

49, 38,
53, 33,
50,
44,41,
50, 64,
67, 69,
50

36,33,4 66,56,6 63,48,
1,20,16, 5,49,38 49,50,
31
,61
39,63

58,46, 32,29, 39,33,4 35,33,2 21,18,2 51,28,6 65,49,
43,52, 30,25, 7,52,57 9,18,23 7,28,20, 1,49,42 60,62,
46,39 17,24
,50
,23
28
,57
51,62
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Table S3. Summary of Clonogenic Assay Colony Counts: Means and St.D. Data
are calculated using SI Appendix, table 2. The values shown in red were obtained in
the experiments where excess of gold constructs was not removed before radiation; the
other data were obtained in the experiments where the excess gold was removed
before radiation
Exp.1 Exp.2

Exp.3 Exp.4 Exp.5 Exp.6 Exp.7 Exp.8 Exp.9 Exp.10 Exp.11 Exp.12 Exp.13

Exp.14 Exp.15 Exp.16 Exp.17

0 Radiation,
100±2 31±4
No Gold

79±8

0 Radiation,
Gold Alone

75±18

49±8 61±8

57±10 51±5

0 Radiation,
Gold-pHLIP
1.5 Gray
Radiation,
No Gold

66±12 15±3

1.5 Gray
Radiation,
Gold Alone

38±7

3 Gray
Radiation,
Gold Alone
3 Gray
Radiation,
Gold-pHLIP

31±9

40±12

1.5 Gray
Radiation,
Gold-pHLIP
3 Gray
Radiation,
No Gold

23±5 39±8

96±10 23±9

54±4 42±5

58±11 69±9

41±7

62±7

60±8

31±9

59±7

56±8

25±5 25±4

52±10 47±9

21±7

38±7

45±9

42±5

30±8

28±4

17±3

22±5 15±3

33±9

41±11 33±8 55±7

29±3

49±6

28±5 29±5

61±12 58±5

36±9

30±10 56±11 52±9

47±7

26±5

46±9

27±7 24±5
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48±12 58±7

51±11

57±6

44±7

47±6

43±9

47±9

44±7

58±5

41±5

45±4

51±8

50±8

Table S4. Summary of Normalized Clonogenic Data for Low pH. Cells were
treated with the constructs at low pH before radiation. The average values from SI
Appendix, table S3 were divided by the average for “0 Radiation, No Gold” for each
experiment. The values shown in red were obtained in the experiments where excess
of gold constructs was not removed before radiation; the other data were obtained in
the experiments where the excess gold was removed before radiation.
Exp.1 Exp.2
0 Radiation,
No Gold

1

Exp.3 Exp.4 Exp.5 Exp.6 Exp.7 Exp.8 Exp.9 Exp.10 Exp.12 Exp.13 Exp.14
1

0 Radiation,
Gold Alone

1

1

1

1

1

1

1

1

0.996

1.072

0.755

1.02

0.61

0.897

0.498

0.652

0.488 0.493 0.331 0.407 0.353

0.563

0.21 0.267 0.357 0.206 0.386 0.204 0.281

0.421

0.947

0 Radiation,
Gold-pHLIP
1.5 Gray
Radiation,
No Gold

0.659

0.493 0.476 0.468 0.629

1.5 Gray
Radiation,
Gold Alone

0.51

1.5 Gray
Radiation,
Gold-pHLIP
3 Gray
Radiation,
No Gold
3 Gray
Radiation,
Gold Alone
3 Gray
Radiation,
Gold-pHLIP

0.6 0.466

0.385

0.299

0.183

0.284

0.385

0.31 0.185 0.365 0.199 0.228

0.331
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Exp.15 Exp.16 Exp.17

1

1

1

1

1

1

0.868

1.018

0.934

0.957

1.175

1.062

Table S5. Summary of Normalized Clonogenic Assay Data for High pH. Cells
were treated with the constructs at normal pH before radiation. This table is analogous
to SI Appendix, table S 4, which is for the low pH experiments.

Exp.11
0 Radiation, No Gold

1.000

0 Radiation, Gold Alone

0.871

0 Radiation, Gold-pHLIP

0.810

1.5 Gray Radiation, No Gold

0.684

1.5 Gray Radiation, Gold Alone

0.650

1.5 Gray Radiation, Gold-pHLIP

0.611

3 Gray Radiation, No Gold

0.339

3 Gray Radiation, Gold Alone

0.304

3 Gray Radiation, Gold-pHLIP

0.340
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Table S6. Detailed Results of ANOVA for 1.5 Gray Radiation.

Model
Normalized Survival = Treatment + Removal + (TreatmentRemoval)
ANOVA Results
Degrees of
Freedom

Sum of
Squares

Mean
Squares

F Value

P Value

Treatment

2

0.421

0.21

10.9

4.9610-5

Removal

1

0.453

0.453

23.5

4.3910-6

Treatment*Removal

2

0.122

0.061

3.2

0.0465

105

2.026

0.019

Residuals

Posthoc Test Results
Difference
in Means

Lower Bound
of 95%
Confidence
Interval

Upper Bound of
95% Confidence
Interval

Adjusted P Value

No Gold vs. Gold-pHLIP

0.136

0.065

0.206

3.6410-5

Gold-pHLIP vs. Gold
Alone

-0.114

-0.209

-0.019

0.015

No Gold vs. Gold Alone

0.022

-0.068

0.111

0.832

Removal vs. NonRemoval

-0.13

-0.184

-0.076

5.9510-6
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Abstract
Enhancing the effect of radiation on tumors would be a significant improvement in
radiation therapy. With radiation enhancement, less radiation could be used to achieve
the same goals, lessening damage to healthy tissue and lessening side effects. Gold
nanoparticles are a promising method for achieving this enhancement, particularly
when the gold nanoparticles are targeted to cancer. This literature review discusses the
properties of gold nanoparticles as well as existing in vivo radiation enhancement
results using both targeted and non-targeted gold nanoparticles.
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Abbreviations

GNP : Gold nanoparticles
PEG : Polyethylene Glycol
kVp : Kilovolt Peak
Gy : Gray
pHLIP : pH-Low Insertion Peptide
IV : Intravenous
CTR : Complete Tumor Regression
DTPA : Diethylenetriamine pentaacetic acid
BSA : Bovine Serum Albumin

Introduction
In radiation therapy for cancer, radiation is delivered after precise calculations so that
a maximum dose is given to the tumor and a minimum dose is given to healthy tissue.
Despite these efforts, radiation still affects healthy tissue. This effect is especially
dangerous when the tumor is located near important organs. Thus, it is important in
radiation therapy to reduce the dose and the damage to healthy tissues and organs(1).
One of the current strategies to reduce radiation is the use of radiation enhancers,
which can absorb and make tumor cells more susceptible to it. They are designed to
improve tumor cell killing, since making a tumor more susceptible to radiation means
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that less radiation can be used. And if less radiation is used, there will be less adverse
effects on normal tissues(2).
Radiation enhancers can include materials like nanoparticles, e.g. carbon nanotubes,
gold nanoparticles and quantum dots. In this paper, we will focus on the use of gold
nanoparticles (GNPs). Gold is a good radiation enhancer. The radiosensitization of
biomolecules by GNPs can be caused by locally increased radiation absorbed energy.
Gold, a high Z material, is capable of absorbing radiation at significantly higher rates
than tissue. The advantage in absorption can grow to about a factor of 100 for certain
keV photon energies (20 keV shown in (3), can be checked in a database (4)).
Additionally, gold nanoparticles that interact with radiation can release a number of
Auger electrons via the Auger effect. The Auger effect occurs when an excited atom
(for example, an ionized gold atom) releases its extra energy in a form of an electron
instead of a photon.
Radiosensitization can also be caused by modified sensitivity of targeted biomolecules
to radiation (5). The efficiency of chemical radiosensitization mechanism is
significantly influenced by the strong binding of GNPs to the biological target as
DNA(5). Jain et al. (6) suggests a possible biological mechanism of radiosensitization
by GNPs even in the absence of radiation, with GNPs potentiating the effect of
bleomycin. The results showed that the GNPs caused chemosensitization to the
radiomimetic agent bleomycin at a range of concentrations with a sensitizer
enhancement ratio similar to that observed for the kilovoltage photons.
Auger electrons have comparatively low energies (approximately 80 keV or less in
gold), and because of this they have a short range of action in tissues. It can result in
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the delivery of a precise and lethal dose in their immediate vicinity. However, this
short range also indicates that gold nanoparticles need to be located within tumors,
near the vital cellular structures, in order to maximize the radiation enhancement
effect(7, 8). This suggests the need for the gold nanoparticles to be targeted to cancer
cells.
In this paper, we will review the use of gold nanoparticles as a radiation enhancer in
vivo. Specific topics include:


Properties of gold nanoparticles



Important Experimental Variables



In vivo radiation enhancement results for non-targeted gold
nanoparticles



Nanoparticle Targeting



In vivo radiation enhancement results for targeted gold nanoparticles

Properties of Gold Nanoparticles
Gold nanoparticles properties include the following:
i)

Gold is an inert material and can be made to be biocompatible using
surface modification, like surface coating of the GNPs (2, 3, 6-17).

ii)

Gold nanoparticles can be linked to biomolecules, either via stabilizers
(polyethylene glycol, maleimide) or directly to sulfhydryl (-SH) groups
of moieties such as peptides, antibodies, small molecules or proteins.
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Tumor targeting can be achieved by conjugating the GNP surface to
peptides, ligands, antibodies or drugs (2, 3, 6-9, 11-14, 16, 18, 19).
iii)

Gold nanoparticles, as any nanoparticle, have a large surface to volume
ratio. The relatively large surface area provides opportunity for
interactions with molecules. Having large number of surface ligands,
gold nanoparticles allow flexible design and multi-functionality by
incorporating mixed ligands (3, 12, 18) .

iv)

The nanoparticles including GNPs exhibit preferential deposition at
tumor sites due to the enhanced permeation and retention (EPR) effect.
This makes them to be effective as drug carriers and radiation
enhancers (1, 8, 16). This is related to the small size of GNPs, and the
leaky vasculature of tumors.

v)

The size of GNPs can be tuned to a wide range (1-1000 nm) and
various shapes (2, 3, 6, 9, 12, 18, 19).

Important Experimental Variables
The following variables are known to affect the amount of radiation enhancement that
the gold nanoparticles are capable of delivering:
Concentration of gold: The concentration of gold nanoparticles in the tumor sites (and
thus the number of gold atoms) affects the radiation enhancement capability. Hainfeld
et al. (20)doubled the concentration of non-targeted gold nanoparticles (from 1.35 to
2.7 grams of Au per kilogram mouse weight), and increased survival by 72% (from
50% to 86%).
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Size, Shape and Surface Chemistry of GNPs: There are various sizes and shapes of
gold nanoparticles available, and this affects their uptake by the cells. Also, surface
chemistry is an important parameter, which affects biodistribution and cellular uptake
of nanoparticles. Chithrani et al. (21) found that the cellular uptake of spherical GNPs
of 14, 30, 50, 74, 100 nm in diameter is size dependent. Cells in vitro had a maximum
uptake for 50 nm sized spherical GNPs. The rod shaped nanoparticles exhibited less
uptake by cells compared to spherical particles. For example, cells took up 500 and
375% more 74 and 14 nm spherical gold nanoparticles than 74 × 14 nm rod-shaped
gold nanoparticles, respectively. The authors noted that in addition to size and shape
of GNPs the surface chemistry might also affect cellular uptake of nanoparticles. Nonhomogeneous coating of nanoparticles with citric acid ligands and presence of cetyl
trimethylammonium bromide (CTAB) molecules at the surface of rod GNPs could
result in lower cellular uptake. In an in vitro study of GNPs as radiation enhancers in
cancer therapy, 50 nm spherical GNPs showed the highest radiosensitization
enhancement factor (REF) (1.42 at 220kVp) compared to gold nanoparticles of 14
and 74 nm (1.20 and 1.26 respectively) (10). 12.1 and 27.3 nm size spherical GNPs
coated with polyethylene glycol (PEG) showed high radiation enhancement compared
to 4.8 and 46.6 nm size, both in vitro and in vivo, with accumulation of GNPs in the
tumor with high concentration (22). This is in contrast to the computation study
performed by McMahon et al.(17) , which predicts an increase in radiation
enhancement with decreasing size of spherical GNPs. Puvanakrishnan et al.(23)
compared cellular uptake for gold nanoshells and gold nanorods. The results indicated
a higher accumulation of smaller rod GNPs in tumor compared to the larger nanoshell
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GNPs . However, the accumulation of nanorods and nanoshells in the liver increased
significantly for higher doses. This suggests that the particle shape and size
significantly affects tumor targeting and confirms that the smaller particles have
enhanced accumulation in tumors compared to larger nanoparticles. Huang et al.
(24)found that GNPs smaller than 10 nm have unique advantages over GNPs greater
than 10 nm in localization and penetration of breast cancer cells, multicellular tumor
spheroids and tumors in mice. The in vivo results showed that 2 and 6 nm tiopronincoated GNPs were distributed throughout the cytoplasm and nucleus whereas 15 nm
samples became aggregated in the cytoplasm. Tumor bearing mice were intravenously
injected with a dose of 5 mg of Au per kg of mice. After 24 hours the amount of gold
in tumor was 2.93 micrograms per gram of tumor for 2 nm, 0.79 micrograms for 6 nm
and 0.14 micrograms for 15 nm particles. Compared to 15 nm GNPs, the 2 nm and 6
nm GNPs were widely distributed in different organs of the body due to small
structures. Histological analysis showed that GNPs had almost no effect on tissues
including liver, spleen, kidney, lung and heart, indicating good tissue biocompatibility
of the GNPs.
Cell Line Used in Studies with GNPs: Radiation enhancement by GNPs is cell line
specific. They enhance the radiation when treated with some cells but not all.
Significant radiosensitization occurred in MDA-MB-231 cells at 160 kVp. However,
no significant radiosensitization was observed in DU 145 or L132 cells, even though
there was uptake of GNPs in both of these cell lines. In an in vitro experiment, uptake
of GNPs was greater in MDA-MB-231 cells than in DU 145 or L132 cells, and hence
radiation enhancement was better in MDA-MB-231 cells. (6).
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Intracellular Localization of GNPs: The location of gold nanoparticles inside of the
cells affects radiation enhancement; for example, a GNP attached to DNA
(Deoxyribonucleic acid) will likely have a greater impact than a GNP in other
locations (for example, the local effect model discussed in (25)). Typically, not
targeted nanoparticles will enter cell via endocytotic pathway and will be trapped in
endosomal/lysosomal compartments and might exit cell via the exocytosis process.
The uptake and removal of particles depend on its size, shape and surface
properties(26). The use of pH Low Insertion Peptides (pHLIP® peptides) to target gold
nanoparticles to cancer cells (in vitro) resulted in location of GNPs to the plasma and
nuclear membranes (7, 15) . Ultra-small Au@tiopronin nanoparticles (2 and 6 nm)
were localized throughout the cytoplasm and nucleus of cancer cells in vitro and in
vivo, whereas 15 nm nanoparticles were found only in the cytoplasm and were
aggregated (24).
The targeting ligands: The targeting ligands enable nanoparticles to bind to cell
surface receptors and enter the cells by receptor mediated endocytosis (18).
Nanoparticles accumulate at the tumor sites due to leaky, immature vasculature due to
enhanced permeability and retention effect (8, 13, 16). Chattopadhyay et al. (27)
discusses the molecular targeting approach, which enables a larger amount of GNPs to
cross the cellular membrane and accumulate in the cancer cell cytoplasm. The
experimental result showed that the GNPs modified with trastuzumab for targeting
HER-2 on breast cancer cells with 100kVp x-rays were more effective in decreasing
the clonogenic cells survival as compared to the non-targeted GNPs (27). Kong et al.
(28) found that the local concentration of GNPs in target locations can be increased by
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localized delivery in comparison to the naked GNPs. 15nm GNPs with
AET(cysteamine) were bound to the cell membrane when treated with MCF-7 cells
whereas 15nm GNPs with Glu were distributed in the cytoplasm when treated with
MCF-7 cells. More GNPs were taken up or bound to MCF-7 cells in case of GluGNPs and AET-GNPs than the naked GNPs. With the combined effect of 200kVp,
10Gy x-rays Glu-GNPs produced decreased cell survival compared to AET- GNPs
(28) . Su et al. (16) used cyclic RGD conjugated with GNP, labeled with Iodine-125
as a radiosensitizer, for tumor targeting and enhanced radio-therapeutic efficacy. The
results depicted consistent apoptosis and the volume loss, indicating effective
suppression of tumor growth due to radiation therapy on the radio-labeled targeting
ligand on GNPs compared to non targeted GNPs.
Biocompatibility of GNPs: Coating gold nanoparticles with polyethylene glycol (PEG)
or bovine serum albumin (BSA) can increase the likelihood of each nanoparticle
reaching the tumor, since chemically modifying the GNPs by organic molecules such
as PEG or BSA helps GNPs to avoid reticuloendothelial system uptake and to
increase circulation time in blood (3, 8). BSA capped GNPs are easy to synthesize,
resulting in uniform size and stability under physiological conditions (8). A nonexhaustive list of similar or related methods includes the following:


Kim et al.(29) found that PEG-coated GNPs had a much longer blood
circulation time (>4 h) than non-PEG-coated GNPs.



PEG coated GNPs can accumulate in mouse sarcoma flank tumors to
concentration 10 times that of muscle and 50 times that of brain (12).
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Puvanakrishnan et al. (23) investigated the effect of PEG-coated gold
nanoshells and gold nanorods, and its tumor targeting efficiency on mice with
a subcutaneous tumor. Mice received an IV injection of single and multiple
doses of gold nanoshells and gold nanorods. The uptake of nanoshells and
nanorods in the tumor was seen to increase for the multiple doses compared to
the single dose. The particle accumulation in tumors for three consecutive
doses was increased by 2 for gold nanoshells and 2.45 for nanorods, compared
to the single dose. Similarly for five consecutive doses the particle
accumulation in tumors was increased by 3 fold for nanoshell GNPs and by 1.6
fold for nanorod GNPs, in comparison to the single dose. The uptake of
smaller PEG-coated gold nanorods was 12 times more compared to the uptake
of larger PEG-coated gold nanoshells in the tumor after 24 hours. The results
from this study suggest that multiple dosing might be an effective method to
increase GNPs accumulation in tumors.
Method of Administration of GNPs to Animals: Direct injection of GNPs by
intra-tumoral administration can aid tumor uptake (15). Intravenous
administration of gold nanoparticles still results in relatively large
accumulation in tumor tissue, due to the enhanced permeability and retention
effect discussed above, which is related to leaky vasculature within tumors (see
for example (14)).

Radiation energy (for photon irradiation): Dose enhancement caused by GNPs has
been observed in kilovoltage and megavoltage beams (6, 10, 20). However, enhanced
cell killing was monitored when cells and GNPs were irradiated with photons in the
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kilovoltage range (9, 11, 30-32). Hainfeld et al. 2008(3) found that dose enhancement
factor depends on both radiation energy and the amount of GNPs.
The relative success of lower energy photons is likely due in part to the fact that, in
general, lower energy photons have a higher absorption probability in gold than higher
energy photons (4). However, lower energy photons also come with the complicating
factor that they are less penetrating, and may not be able to reach tumors deeper than
skin depth. For most clinical purpose MeV photons are used due to the fact that for
high energy photons , the energy is distributed over a wide range in soft tissue (9).
Chang et al. (31) used 6MeV electrons to irradiate a 1-inch diameter tumor region of
the leg of the mouse model. Chitrani et al.(10) used low energy kVp and high energy
MVp for irradiating cells. The results showed that greater radiation sensitization was
seen for kVp compared to MVp for the cell experiments. Further it was evidently
found for the first time that radiation sensitization was enhanced even at the clinically
relevant high X-ray energy of 6MVp. Also Jain et al.(6) showed a radiosensitization
effect on cells at MV X-ray energies as well as at kV energies. The MDA-MB-231
cells were seen to be radiosensitized at MV X-ray energies. Popovtzer et al.(33)
showed a radiosensitization effect when cetuximab coated GNPs were used for tumor
targeting in a clinically relevant radiation treatment of 6MV energy. The results
showed that there was no increase in tumor diameter at all for CTX-GNP+RT
compared to 1.0cm increase in tumor diameter for the control case.
If the mechanism of cancer destruction is primarily Auger electrons after the
photoelectric effect, an intriguing photon energy to use would be an energy just above
the k-shell energy of gold, 80.7 keV (see for example, the X-Ray Attenuation
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Database from the National Institute of Standards and Technology). Most interactions
would occur with the k-shell electrons, and a photon energy just above the k-shell
energy would take advantage of two factors: (1) the photoelectron released would be
of low energy, and thus would be localized like the Auger electrons; (2) the
photoelectric effect has a sharp spike in absorption coefficient at each shell energy,
including the k-shell energy.
Radiation dose: Increasing the radiation dose from 30 Gy to 35 Gy increases the
survival rate of the mice for the same KeV energy of 100 kVp x-rays (34). However,
at some point there must be a radiation dose of maximum effectiveness for a given
experimental setup, since an extremely high dose of radiation would kill the
experimental subjects.
Radiation type: In most of the experiments with gold nanoparticles photon irradiation
was used, but experiments have also been done using proton, electron and LET
radiation. Kim et al. (35) found an increase in survival in mice treated with protons
and either gold nanoparticles or magnetic nanoparticles. Chang et al (31) found an
increase in radiation enhancement from gold nanoparticles using electron radiation.
Liu et al. (36) found that the survival fraction for HeLa cells when irradiated with high
LET carbon ions was significantly less than when irradiated with low LET X-rays.

In vivo radiation enhancement results for non-targeted gold nanoparticles
Although many gold nanoparticle radiation enhancement studies have been done in
vitro, only a few studies have been performed in vivo. No specific tumor targeting was
utilized in the studies described in this section.
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Hainfeld et al.(20): The pioneer study of use of GNPs as a radiation enhancement was
done in BALB/C mice bearing subcutaneous EMT-mammary carcinoma. In one
experiment, the treatment group of mice received 1.9 nm GNPs at a concentration of
1.35 grams of gold per kg of mouse, injected intravenously into the tail, with
irradiation started 2 minutes later. The animals received 30 Gy of radiation from a 250
kVp x-ray machine. These mice survived with only 1 of 10 mice having a visible
tumor after 1 month, compared to no retardation of tumor growth for mice receiving
only x-rays or gold.
In a second experiment, 50% of mice survived for one year after being given 1.35
grams of gold per kg of mouse and 26 Gy of radiation. In contrast, 86% of mice
survived after being given 2.7 grams of gold per kg of mouse. 20% of mice survived
with just radiation, and 0% of mice survived with just gold or with no treatment.
Other results showed that after injection of GNPs, many blood vessels became visible
due to the gold absorption. Pharmacokinetics showed an early rapid rise followed by a
slower clearance rate. Gold in tumor peaked at 7.0 ± 1.6 min and fell to half of its peak
value at 41.2 ± 19.5 min; gold in muscle peaked at 5.3 ± 0.6 min and fell to half at
24.2 ± 2.6 min. The data showed that the GNPs cleared nearly twice as fast from
normal muscle as from tumor. The injected gold solution was dark black/brown and at
the periphery of some tumors was similarly dark. These tumor periphery results
showed almost twice the gold concentration of the main tumor mass. The periphery of
one tumor contained 6.5 mg Au/g, with a tumor to normal tissue ratio of 8.6. This
leads to the fact that a targeting molecule, such as an antibody or peptide, attached to
the gold nanoparticle would further improve the tumor specificity and distribution of
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GNPs within a tumor. The GNPs were shown to be non-toxic to the mice, based on
preliminary toxicity testing.

Hainfeld et al.(37): In this study, Hainfeld et al. tested the effects of radiation dose,
radiation energy and a preheating strategy. C3H/HeJ mice were given subcutaneous
highly radiation resistant SCCVII head and neck squamous cell carcinoma. 1.9 nm
GNPs were found to be more effective at 42 Gy than at 30 Gy for the same radiation
energy (68 keV median energy photons). GNPs were also found to be more effective
when used at 68 keV than at 157 keV for the same radiation dose (42 Gy). Further,
GNPs were found to be more effective at 50.6 Gy, 157 keV than at 44 Gy, 157 keV.
The effect of preheating the mice was also investigated. Mice were preheated for 1217 mins by submerging the legs of anesthetized mice containing tumor in 44oC water
bath. GNPs were then injected (1.9 g/kg body weight) and the mice were heated again
for 3 mins, and then irradiated a minute later with 30 Gy, 68 keV. As a result it was
seen that the GNPs enhanced the synergy of hyperthermia and radiation therapy at
sufficiently high radiation doses (30 Gy, compared to 15 and 23 Gy). The
experimental results showed that there was not any damage in the leg of mice and that
the tumor doubling time was 52 days for heat + radiation + gold compared to 45 days
for radiation alone. The surviving fraction was 79% for heat + radiation + gold
compared to 14% for radiation alone.
Hainfeld et al.(34): In this study, Hainfeld et al. treated brain cancer in mice using
gold nanoparticles. 50% long-term survival (>1 year) was found using B6C3f1 mice
bearing Tu-2449 brain tumors. Irradiation (100 kVp x-rays, 30 Gy) occurred 15 hours
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after injection of 11 nm GNPs at a concentration of 4 grams of gold per kg of mouse.
0% long-term survival was found for mice given no treatment, GNPs only and
radiation only.
Similarly, for a slightly higher radiation dose of 35 Gy, 56% long-term survival was
found compared to 0% survival of mice with no treatment and 18% long-term survival
for radiation only.
Further results showed that IV injected GNPs specifically localized in brain glioma in
a 19:1 tumor to normal brain ratio. The micro CT measured by the tumor uptake of 1.5
± 0.2% (weight by weight) gold, which was considered to be the highest gold
concentration ever achieved in tumor by IV injection. Atomic absorption spectroscopy
measured the uptake to be 1.5 ± 0.2% (weight by weight) gold. The GNPs were
initially distributed throughout the tumor, very different from the subcutaneous tumors
where GNPs of 15 nm were largely confined to the tumor periphery. The amount of
gold delivered was high enough to multiply a radiotherapy dose of tumor by a
calculated factor of approximately 300%. Hainfeld predicts this is an indication of
difference in tumor and vasculature growth pattern, perhaps indicating the brain tumor
cells are more migratory, thus not severely compressing central blood vessels limiting
internal blood flow. No toxicity was seen for the concentration of gold used in this
study.
Chang et al.(31): Chang et al. used electron radiation with gold nanoparticles.
C57BL/6 mice with B16F10 melanoma were injected (IV) with 13 nm GNP at a
concentration of 1 gram gold per kg of mouse. 24 hours later, 25 gray of 6 MeV
electron radiation was given using a Varian 2100C linear accelerator.
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The results showed a retarded tumor growth and increase in survival of mice receiving
GNPs followed by radiation compared to the radiation alone, GNPs alone and control
groups of mice. Survival of mice treated with gold nanoparticles and radiation was
60% after 2 months, whereas survival was less than 20% for radiation treatment alone
and 0% for gold nanoparticles alone or no treatment.
Biodistribution of GNPs 24 hours post IV injection of GNPs showed the accumulation
of GNPs inside the tumor, with a tumor to tumor surrounding muscle gold ratio of
6.4:1. Also, higher concentrations of GNPs were found in the liver and spleen,
indicating uptake of gold by the reticuloendothelial system.
The number of apoptotic cells detected in tumor by a TUNEL assay was significantly
higher in mice treated with GNPs followed by radiation than in mice receiving only
radiation, GNPs alone and control groups.
Compared to Hainfeld et al.(20), fewer GNPs were injected IV into the mice in Chang
et al. 2008 (31) (2.7 g Au/kg versus 1 g Au/kg). Additionally, the irradiation was
done 24 hours after injection, versus 2 minutes after injection in Hainfeld et al.
(2004)(20).
Bobyk et al.(38): Bobyk et al. studied the effect of gold nanoparticles and radiation in
rats with brain tumors. Male Fischer rats bearing F 98 glioma cells were
intracerebrally injected by 5 microliters of 15 nm GNP (25 mg/mL or 50 mg/mL) 20
minutes before irradiation using 88 keV x-rays with a dose of 15 Gy.
The untreated groups of rats had a mean survival time of 23.8 ± 1.6 days and the rats
receiving GNPs alone had a mean survival time of 24.9 ± 0.8 days and 23.3 ± 0.7 days
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for 25 mg/mL and 50 mg/mL. This suggests that the GNPs alone did not improve the
animal life span.
The group of rats that received radiation alone had a mean survival time of 33 ± 2.7
days, an increase of 38.8%. The group of rats receiving GNPs and x-rays had mean
survival times of 34.9 ± 1.7 days (25 mg/mL) and 41.6 ± 3.2 days (50 mg/mL). Thus,
the higher concentration of GNPs, combined with radiation, showed a 74% increase in
mean survival time. TEM results showed that GNPs are trapped by endosomes before
being fused with lysosomes in vitro. In vivo results also showed the internalization of
15 nm GNPs by the endosomal pathway in cells on brain tissue biopsies but GNPs
were not observed in the mitochondria, Golgi complex or nucleus. Additionally, 15
nm GNPs were observed in the healthy and tumor brain tissues by electron
microscopy at all time points, up to 6 days after GNP injection. The clinical signs of
toxicity was not seen during the observation period on any mice which received the
lowest concentrations of GNPs. At the same concentration of GNPs for different sizes
the smaller ones are found to be more toxic than the larger ones in vivo.
Joh et al.(39) coated 12 nm gold cores by PEG (polyethylene glycol) to make GNPs of
hydrodynamic diameter of 23 nm. These GNPs were injected intravenously in female
athymic mice bearing the most prevalent and aggressive primary brain tumor U 251.
48 hours post injection of pegylated GNPs (1.25 grams of gold per kg of mouse), the
brain of the mice was given a radiation dose of 20 Gy from a 175 kVp small animal
radiation research platform. The combined treatment of GNPs and radiation therapy
increased the DNA damage to brain blood vessels in vivo, resulting in increased
survival of mice and delayed tumor growth. Joh et al. interpret these results as
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suggesting that radiation-induced blood brain barrier disruption can be leveraged to
improve the tumor-tissue targeting of GNPs, which would further optimize the
radiation enhancement of brain tumors by GNPs. The GNP toxicity in vivo was very
small in this study, as shown by the preliminary data.
Zhang et al.(22) studied size-dependent radiation enhancement using PEG-coated
GNPs. PEG-coated GNPs of sizes 4.8, 12.1, 27.3 and 46.6 nm (concentration 4 mg of
gold per kg of mouse) were injected intraperitoneally to female BALB/C mice bearing
U14 tumors. The tumors were then irradiated by 5 Gy of gamma radiation. Mice were
sacrificed after 24 days. The results indicated that all sizes of PEG-coated GNPs
decreased the tumor volume and weight after 5 Gy of radiation, but 12.1 and 27.3 nm
PEG coated GNPs induced appreciable decreases of tumor volume and weight,
indicating that these sizes of particles have greater radiation enhancement effects
compared to 4.8 and 46.6 nm particles. The toxicity in vivo was appreciably less on
the basis of immune response and blood biochemistry. However the liver was slightly
damaged. Also it was found that the GSH-protected GNPs had efficient clearance
through the kidney.
Kim et al.(35): Kim et al. studied the effects of proton radiation combined with gold
and iron nanoparticles in mice. Gold nanoparticles (coated with DTPA,
diethylenetriamine pentaacetic acid-cysteine conjugate) or iron nanoparticles (coated
with alginate) of sizes 14 ± 1.2 nm and 10.6 ± 0.8 nm respectively were injected
intravenously to Balb/c mice with CT26 tumors either on their leg or flank. The
injected dose of particles was either 100 or 300 mg of metal per kg mouse. 24 hours
after injection, proton irradiation was given with radiation doses of 10-41 gray. Two
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different strategies of proton radiation were employed: protons that were absorbed in
the mouse (with the Bragg peak located on the tumor) and protons that traversed
through the mouse.
The results for tumor uptake showed that 15 minutes after injection of particles the
tumor concentration was 137.4 ± 50.2 micrograms of gold per gram of tissue or 56.6 ±
18.2 micrograms of iron per gram of tissue, while the corresponding muscle
concentration were 7.5 micrograms of gold per gram and 6.5 micrograms of iron per
gram tissue. The tumor to normal tissue ratio was 18.3 for gold and 8.7 for iron after
15 minutes; after 24 hours it was 169.7 for gold and 88 for iron, thus enabling
enhanced tumor dose deposition. The ratio of tissue uptake to total injected dose was
less than 1% after administration of both 100 and 300 mg of metal per kg of mouse.

In the irradiation experiment, mice receiving a gold or iron nanoparticle injection prior
to various doses from the proton beam demonstrated 58% (absorbed protons) or 64100% (traversing protons) long-term survival. All animals that were not given
radiation died in 2-4 weeks. All proton radiation alone groups showed slowed tumor
growth and resulted in only 13% (absorbed protons) or 11% (traversing protons) longterm remissions.
Complete tumor regression (CTR) in mice showed a direct dependence on proton and
nanoparticle doses. Either 45 Gy proton alone or 21 Gy irradiation with 300 mg/kg
magnetic nanoparticles injections produced 100% CTR in mice. In vitro experiments
showed an increase in the generation of reactive oxygen species from the metallic
nanoparticle and proton radiation treatment. Gold nanoparticles had greater tumor
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uptake and a more rapid clearance for normal tissue compared with iron nanoparticles,
due to different surface coatings.
Chen et al.(8): Chen et al. exploits the potential of BSA capped GNPs as an efficient
sensitizer for glioblastoma, both in vitro and in vivo, on radiotherapy. Clonogenic
assay was performed on U87 glioblastoma cells with or without BSA - GNPs of
28nm hydrodynamic diameter with a series of doses in between 0-8 Gy at 160kVp Xray. Also 250uL of, 1.3mg mL-1 BSA-GNPs was injected intravenously to the mice
model having U87 glioblastoma tumor of diameter 0.8-1cm. The mice were then
irradiated by 160kVp X rays with a dose of 3Gy after 2hr and 2Gy after 24 hr of
treatment. The tumor volume was calculated every alternate day .All the mice were
euthanized after 20 days of the treatment and the tumors were weighted.

The in vitro RT showed that the percentage of cell apoptosis was larger for BSAGNPs + RT followed by RT alone then BSA-GNPs and the minimum percentage of
apoptosis was for the control group. The in vivo RT showed that the relative tumor
volume after 20 days of treatment was maximum for the control group and minimum
for BSA-GNP + RT. The data obtained inferred that BSA-GNP + RT showed
maximum tumor regression while X ray alone slowed down the tumor growth while
BSA-GNP alone didn’t affect tumor growth compared to control group of mice.

The weight of tumor for 4 different cases were in accordance with the results obtained
for relative tumor volume, meaning that the weight of tumor was minimum for BSAGNP-RT and maximum for the control group. There was rapid clearance of GNP level
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from the mice after the administration of BSA-GNPs and the in vivo toxicity of BSAGNPs was determined by ICP-AES analysis of GNP level after the treatment of BSAGNPs. This analysis showed no toxicity.

Nanoparticle Targeting:
Successful targeting increases the likelihood that each gold nanoparticle will reach the
tumor. Thus, there is the potential for targeted gold nanoparticles to improve the
radiation enhancement effect. This is particularly true when the primary benefit from
gold nanoparticles comes from Auger electrons, which have a short range, as
discussed in the introduction. In addition to locating gold nanoparticles to cells, the
resulting intercellular localization is also important, as discussed above. Targeting
strategies can be divided into two categories: those that use cancer-targeting
molecules, and other methods that do not.
Cancer cell targeting molecules:
More specific tumor targeting can be done by surface conjugation (attachment) of
antibodies, peptides and other tumor targeting molecules (12). This can improve the
therapeutic index (16, 40). Conjugating gold nanoparticles with targeting molecules
enhances the interaction of the GNPs with the cell surface by enabling the GNPs to
bind to the cell surface receptors and enter cells by receptor-mediated endocytosis
(18). A non-exhaustive list of targeting molecules used with gold nanoparticles (either
in vitro or in vivo) includes the following strategies:
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Glucose capped GNPs are designed to take advantage of an increased
cancer cell requirement for glucose in order to target the cell cytoplasm
(28).



pH-Low Insertion Peptide (pHLIP® peptide) conjugated 1.4 nm GNPs
target tumor acidity, which is achieved in a result of membrane-associated
folding of pHLIP® peptide . Peptides of the pHLIP® family can tether
cargo nanoparticles to the surface of cells in diseased tissues, and it can
move cell-impermeable cargo molecules across the membrane into the
cytoplasm (41-43). pHLIP® peptide has been shown to increase uptake of
gold by a factor of approximately 5-10 in mouse tumors (15).



Antibodies such as trastuzumab have been successfully used to modify
GNPs. Trastuzumab conjugated GNPs has been used for targeting MDAMB-361 tumors in athymic mice, and combined with x-rays the tumors
were reduced to half of their volume at 4 months compared with the
treatment by x-rays alone (27).



GNPs functionalized with RGD peptide (Arg-Gly-Asp), NLS (Nuclear
Localization signal) peptide (H-Cys-Gly-Gly-Arg-Lys-Lys-Arg-Arg-GlnArg-Arg-Arg-Ala-Pro-OH) and pentapeptide (H-Cys-Ala-Leu-Asn-AsnOH) were shown to enhance tumor uptake of GNPs (26).



The conjugation of RGD

peptides to radiolabeled GNPs produced

biocompatible and stable multimeric systems with target-specific molecular
recognition. The properties listed below which are demonstrated by
54

177

Lu-

GNP-RGD compared to the other radiopharmaceuticals make it suitable to
be used as a molecular targeting radiotherapy agent.

177

Lu-GNP-RGD

leads to significant reduction in VEGF gene expression, helps to reduce
tumor metabolic activity, induces less tumor progression, fewer
intratumoral vessel, yields more uptake and retention in tumor (44).


Choi et al.(45) modified the surface of 50 nm GNPs with PEG and
transferrin (a tumor targeting ligand) to make particles of size 80 nm.
4.5x1011 particles were injected IV to female A/J mice containing
subcutaneous Neuro2A tumors, and all organs were collected after 24
hours. The results showed that the GNP localizations within a particular
organ are influenced by the transferrin content whereas the nanoparticle
accumulations in the tumors and other organs are independent of
transferrin.



Shah et al.(46) found that 30 nm PEG-coated GNPs interact with blood
cells in vivo, which results in longer blood circulation that correlates
strongly with tumor uptake. In tumors, accumulation was increased by 10
times using GNPs conjugated with a bioactive ligand (tumor necrosis
factor) compared to untargeted GNPs.

In vivo radiation enhancement results for targeted gold nanoparticles
To the author’s knowledge, there are only a few papers currently existing where
targeted gold nanoparticles are used to enhance radiation effects on tumor in vivo.
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Chattopadhyay et al.(27) used 30 nm GNPs conjugated with monoclonal antibody
transtuzumab (AuT) to target the human epidermal growth factor receptor-2 (HER-2).
Female athymic CD1nu/nu mice bearing MDA-MB-361 cells were intra-tumorally
injected with 4.8 mg/g of AuT (0.8 mg of GNPs per gram of mouse) followed by 11
Gy, 100 KVp x-rays after 24 hours. They found a 46% reduction in tumor volume at 4
months as compared to treatment with x-rays alone (16% increase in tumor
volume).The analysis of the body weight index curves for different mice groups
revealed no normal tissue toxicity by the use of Au-Ts with RT.
Su et al.(16) used 20nm GNPs conjugated with clinically used therapeutic
radionuclide Iodine-125 labeled to cRGD as a tumor targeted radiosensitizer. IV
injection of 100uL(containing 1mg Au) was given to Balb/c mice bearing NCI-H446
lung tumors. Co-60 source, 5Gy γ rays were used to irradiate the tumor tissues. RT
effect was assessed by IV injection of Tc-99m-Annexin V (18.5MBq/mouse) after 2
days of treatment for evaluation of apoptosis induced by radiosensitized RT and
SPECT performed.
The degree of apoptosis which is shown in numerical value was measured for 5
different groups and the results showed that there was a significant difference between
targeted radiosensitizer based RT (cRGD-GNP-RT) (9.8±2.7) and non-targeted
radiosensitizer (GNP+RT) based RT (5.5±1.4) (P=0.011). Also, a significant
difference was seen between radiolabeled (I-125) cRGD-GNP-RT (11.2±2.1) and nontargeted radiosensitizer based RT (5.5±1.4) (P<0.01). However, a significant
difference was not seen between the treated and untreated cases between I-125cRGD-GNP-RT (11.2±2.1) and cRGD-GNP-RT(9.8±2.7) (P=0.093). This showed that
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the radiosensitivity was enhanced by the targeting effect. The above results show that
I-125 showed the therapeutic effect but the improvement compared to cRGD-GNP-RT
was not statistically significant. However the proper choice of more effective
radionuclide like I-131 can heavily enhance of therapeutic effect.
Also, after 21 days the percentage volume increase in tumor for different groups of
mice was also measured and found that it was maximum in control (312.1%±96.9%),
then in RT alone (137.1%±35.5%), then in GNP+RT(85.5%±44.2%). However the
increase in tumor volume was suppressed to 33.1%±17.1% for cRGD-GNP-RTand
was even less increase (15.2%±17.8%) for the I-125- cRGD-GNP-RT.

Also, the functionalized PEG which was used in this research showed good stability
and clearance avoiding the uptake by RES. The in vivo toxicity of PEG covered GNPs
and cRGD-GNPs was found to be low which was verified because there was no
obvious loss of weight of mice.

Popovtzer et al.(33) used 1 mg of cetuximab(CTX) alone or 200uL; 25mg mL-1 Au of
30nm with Ig G or CTX coating, injected IV into the tail vein of mice having a A431
head and neck cancer model of diameter 10mm, then irradiated after 24 hrs with 6MV,
25Gy X-ray. In contrary to the results obtained by Hainfeld et .al where there was the
shrinkage of tumor, here the results showed that there was no increase in tumor
diameter at all for CTX-GNP+RT compared to 1.0cm increase in tumor diameter for
the control case, 0.4cm for CTX+RT, 0.6 for Ig G-GNP+RT, 0.3cm for RT only and
0.9cm for CTX only cases. This shows that the radiation is enhanced by the tumor
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targeted GNPs. A set of experiments to study the biological mechanism of
radiosensitized GNPs was done. Decreased vasculatization in tumors was seen after 1
and 6 weeks of the treatment in CTX-GNP+RT group than control, RT only and
CTX+RT groups. Also Tunnel assay results showed that apoptosis was higher after 1
week and less apoptosis after 6 weeks of treatment in CTX-GNP+RT group compared
to RT only group. And other results showed that the level of proliferation and tissue
repair was reduced in CTX-GNP+RT group compared to other groups.. Further, no
cytotoxic effect was seen on the mice.

Conclusion
The papers reviewed in this article demonstrate the potential effectiveness of gold
nanoparticles in the enhancement of radiation of tumors. Major results and
methodologies are summarized in Table 1. Future experiments with gold nanoparticles
and radiotherapy will likely involve the following areas: trials in humans, experiments
using targeted gold nanoparticles and different radiation energies/types.
The eventual goal of gold nanoparticle treatments is to become viable for use in
humans. One potential roadblock is that treatment with kilo-voltage x-rays is only
capable of penetrating human tissue to a shallow depth. Perhaps trials using this
treatment could be done starting with melanoma or other tumors, which could be
accessed via catheterization, and future advances in engineering could help to
eliminate this roadblock.
The roadblock mentioned in the paragraph above may also inspire more work with
different radiation energies and radiation types. For example, the result of Kim et al.
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(35) with protons seems particularly promising. Additionally, in vitro studies (6, 10)
have shown radiation enhancement with gold nanoparticles and higher energy
photons, although the enhancement is generally somewhat less than kilo-voltage
photon results.
Regardless of the radiation type, it appears that tumor targeting will be of great use in
this type of therapy. To conclude, we can say that GNPs modified with tumor
targeting agents as pHLIP, cetuximab, cRGD and trastuzumab successfully enhanced
the radio sensitization of GNPs which can lead to more effective clinical radiotherapy
with less toxicity in near future(7, 16, 27, 33). Additional trials with other targeting
methods would be beneficial and important.
In summary, gold nanoparticles are a promising research area with the potential to
reduce the amount of radiation necessary in cancer treatments. Successful
experimental work has already been done in this area, including work in mammals.
More work is needed, and this future work has the potential of pushing the field into
clinical relevance.
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Table 1: Summary of major in vivo experimental results
Coating
of GNPs

Size
GN Time to
Radiation
Ps, RT
nm

Year

Animal
model

Tumor model

Hainfeld

2004

Balb/C
mice

EMT -6:
murine
mammary
carcinoma

1.9

Chang

2008

C57BL/6
mice

B16F10:
murine
melanoma

Hainfeld

2010

C3H/HeJ
mice

SCCVII: head
and neck
squamous
carcinoma

First author

13

24 h

electrons
6 MeV

25

1.9

1m

x-rays
68 keV
157keV

30
42
RT only
44
Au+RT
50.6

x-rays
100 kVp

11

Control
Au only
RT only
Au+RT

Intratumoral
(IT ) injection
0.8mg Au or
4.8mg/g tumor

5

Control
Au only
RT only
Au+RT

Intraperitoneal(I
P) injection
4mg/kg

15

Control
Au only
RT only
Au+RT

Intracerebral
infusion (5
µL)(5µL)
25mg/mL
50mg/mL

30

24 h

Zhang

Female
BALB/c
mice

4.8
6.6
12.1
27.3

soon
after
Γ-rays
the
injectio

PEG

2013

Fischer
rats

F98: rat glioma

2013

B6C3f1
mice

T u-2449:
murine highly
malignant brain
tumor

2013

nude
female
athymic
mice

U251: human
glioblastoma

PEG

2012

Balb/c
mice

CT 26: murine
colon
carcinoma

DT PA+
cysteine
14
24 h
FeNPs+algi 10.6
nate

Chen

2015

Nude
athymic
mice

U87:glioblasto
BSA
ma

Su

2015

Balb/c
mice

NCIIodineH446:human
20
125+cRGD
lung carcinoma

2016

A431:
squamous head
Nude mice
I g G CT X
and neck
carcinoma

Bobyk

Hainfeld

Joh

Kim

Popovtzer

IV injection
1.35gAu/kg
2.7g Au/kg

2m

30
26

MDA-MB-361:
CD1 nude human breast
T rastumice
adenocarcinom zumab
a
U14: murine
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Abstract
Biological indicators would be of use in radiation dosimetry in situations where an
exposed person is not wearing a dosimeter, or when physical dosimeters are
insufficient to estimate the risk caused by the radiation exposure. In this work, we
investigate the use of gene expression as a dosimeter. Gene expression analysis was
done on 15,222 genes of Drosophila melanogaster (fruit flies) at days 2, 10 and 20
post irradiation, with x-ray exposures of 10, 1000, 5000, 10000 and 20000 roentgens.
Several genes were identified which could serve as a bio dosimeter in an irradiated
drosophila melanogaster model. Many of these genes have human homologues. 6
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genes showed a linear response (R2 > 0.9) with dose at all time points. One of these
genes, Irbp, is a known DNA repair gene and has a human homologue (XRCC6). The
lowest dose, 10 R, is very low for fruit flies. If the lowest dose is excluded, 13 genes
showed a linear response with dose at all time points. This includes 5 of 6 genes that
were linear with all radiation doses included. Of these 13 genes, 4 have human
homologues and 8 have known functions. The expression of this panel of genes,
particularly those with human homologues, could potentially be used as the biological
indicator of radiation exposure in dosimetry applications.
Keywords: gene expression, radiation biology, radiation dosimetry

Introduction
In the occurrence of a large-scale nuclear event, such as those at Hiroshima, Nagasaki,
Chernobyl and Fukushima Daiichi, the measurement of radiation dose in exposed
humans can be of crucial importance to survival (1, 2). However, in this situation it is
very likely that many people who are exposed will not be wearing dosimeters. Thus, a
method of estimating radiation dose to a patient without a dosimeter would be a very
useful procedure.
One possible methodology for this procedure is the use of gene expression
[polymerase chain reaction (PCR), gene sequencing, microarray analysis, and other
methods]. The hypothesis is that the expression of genes will change due to the
absorbed radiation, and that this change can aid or even substitute for physical
dosimeters and act as a biomarker to estimate the distributed dose or the overall
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exposure. It also helps then to predict the long-term risks of both acute and chronic
exposure (3-6).
In addition to not requiring equipment, such as a dosimeter, another potential
advantage of a gene-expression dosimeter is the time scale over which the
measurements can be made. Even after the radiation exposure has taken place, the
biological indicators for bio dosimetry can still be determined. This would certainly be
an advantage compared to the physical dosimetry (7). Some biodosimetric techniques
could be used long times after exposure (from 6mths to more than 50 years) which
makes it unique compared to the requirements for methods used for immediate dose
estimation (8).
Biological dosimetry not only provides information about the range of radiation dose
but also along with this provides information about the individual radio sensitivity,
which depends on age, smoking habits or other environmental toxins. Thus, biological
indicators are also a measure of the biological, medical radiation damage. Hence, we
can predict about the possible radiation damage by the determination of biological
indicators (5, 7, 9, 10).
The possibility of using gene expression changes has been an exciting method to
measure and predict the damage due to ionizing radiation. The exposure of cells or
animals to ionizing radiation may cause DNA damage and trigger the highly complex
molecular response, resulting in changes of gene expression. These molecular
responses may provide the prospective indicator of exposure(1, 3). Previous work in
this area showed that the variation in the response of genes is due to dose, dose rate,
radiation quality and time after radiation exposure. This suggests that gene expression
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analysis may be an informative marker of radiation exposure and hence can be used as
a potential biomarker. It is important to understand the cellular response to ionizing
radiation or biological effects of radiation exposure in order to develop the predictive
markers for the risk assessment due to radiation exposure on humans(1). The rigorous
research going on in genomics and bioinformatics enables the development of gene
expression profiling as a useful biological indicator of radiation exposure (10, 11).
Work on this area until now has shown that the fold change in gene expression in
response to radiation must be measured directly to develop a gene expression
biomonitor. The expression of the genes would then be a suitable biomarker of
radiation exposure (6). The biodosimetry platform obtained by the experiment could
also be used for personalized monitoring of radiotherapy treatments received by
patients (12).
Several studies have been done to identify the potential biomarkers of radiation
exposure. Tucker et al 2013 used reverse transcription real time PCR (qPCR) to
quantify the expression of selected 106 genes as a function of time up to 7 days post
exposure and concluded that the gene expression analysis by qPCR shows a promising
method for radiation bio dosimetry. In their experiment the mice were exposed to C060 gamma rays source at doses from 0 to 10Gy. The result showed that only 4-7
different genes explained the variance (R2) ≥ 0.69 whereas for the receiver operator
characteristics (a measure of sensitivity and specificity) were ≥ 0.93 at each time
point. At radiation doses up to 6 Gy, the dosimetry was very accurate. Above 6 Gy,
the gene expression dosimetry had limitation. Similar analysis in humans could be
done to assess exposures in mass casualty situations (5).
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Gene expression analysis in response to radiation was done in human lymphocytes and
peripheral blood leukocytes using three different techniques: microarray, multiplex
quantitiative real time PCR (MQRT-PCR) and nCounter Analysis System. A set of
genes was found to be suitable for biological dosimetry using peripheral blood. Four
of the genes (CDKN1A, GADD45A, PHPT1, and CCNG1) show good agreement
between the three methods and the up-regulation of expression in blood and
lymphocytes was detected by all the three techniques. These biomarkers could
potentially be used for monitoring radiation exposure during radiotherapy and
radiological incidents (13).
A novel study was done using blood from patients receiving targeted radiotherapy
(131I-mIBG) to characterize biomarkers that may be useful for bio dosimetry. As an
alternative biodosimety approach, real time PCR analysis was done for the gene
expression and the data showed that transcripts which have already been proven as
biomarkers of external exposures in radiotherapy patients are also good early
indicators of internal exposure. Three transcripts showed that modulation in gene
expression were still significant enough to differentiate between exposed and
unexposed samples after 96 hrs of radiopharmaceutical treatment. A bio dosimetry
model for gene expression was developed to predict absorbed dose based on
modulation of gene transcripts within whole blood. Thus, this biodosimetry for
internal radiation dose or the panel of responsive genes obtained from this study could
be used for establishing triage in affected areas due to dirty bombs or nuclear reactor
accidents at least by rapidly sorting out the

131
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I-exposed from unexposed individuals.

Thus, these selected genes could be strong biomarkers of both external and internal
exposures to humans (14).
A comprehensive analysis of bone marrow endothelial cell (BMEC ) gene expression
over time in wild type mice after total body irradiation of 5 Gy was done with a
particular focus on the secreted gene products. This study is done to characterize the
molecular response of BMECs to ionizing radiation to identify the cellular
mechanisms and paracrine factors through which BMECs regulate hematopoietic
regeneration. The result of a microarray experiment showed that the gene expression
of BMECs is altered within 24 hrs after total body irradiation of 5 Gy and by 14 days
this molecular response is resolved. And a number of genes that encode secreted
proteins are strongly upregulated (Inhbb, Ccl2, Ptn) and are down regulated (Chl1,
Galnt10, Ryk, Pon2, Sdha) more than 10 fold in ECs in response to radiation after 6h
(15).
Amundson et al (1999) showed the dose/response relationship for the induction of 5
genes (CDKN1A, GADD45, MDM2, ATF3 and BAX) exposed to γ rays between the
doses of 2-50 cGy. As a follow up, Amundson et al. (2003) studied the dose response
relationships by reducing the dose rate over three orders of magnitude and found some
protection against the induction of apoptosis. They studied the response of 10 cGy and
less exposure of γ rays in the ML-1 human cell line and showed that the gene
expression could be triggered by the low doses. At different dose responses between 2
and 50 cGy, a linear increase in expression of three genes CDKN1A, GADD45A and
MDM2 was observed in the cell line ML-1, whereas dose rate effect was observed
only for GADD45A and CDKN1A.The data obtained from the microarray analysis on
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RNA samples 2 hours post irradiation with low dose y rays indicate that some genes
show a dose rate effect while others don’t. This indicates the potential usefulness of
gene expression as a biomarker for radiation exposure (4).
Stassen et al. (2003) examined 1176 genes expressed by MCF-7 human mammary
carcinoma cells exposed to 2 and 6 Gy of X rays and found that six of them were
radiation induced gene targets over 1(3 genes), 2(2 genes) and 3(1 gene) days which
was confirmed by quantitative reverse transcription PCR (RTQ-PCR). Of those six
(GLUT-1, PCKI, WAF-1, ISGF3G, MRP8, PSME3) the last three were novel gene
targets showing a correlation with radiation dose and clonogenicity which suggested
an individual dose dependency for all selected genes (16).
Omaruddin et al. (2013) examined the gene expression of the genes MADH7, SEC
PRO and CC3 using relative quantitative RT – PCR in blood samples of patients
before and after undergoing radiation therapy. This gave a wide range of values,
stating the complexity of the response. SEC PRO was found to be down-regulated,
while the gene MADH7 was found to be up-regulated in most of the patients. So the
gene MADH7 could be used as a molecular marker for radiation exposure (6).
Filiano et al. (2011) performed gene expression analysis using real time quantitative
PCR in blood samples from cancer patients undergoing total body irradiation. A set of
eight biodosimetry genes (ACTA2, BBC3, CCNG1, CDKN1A, GADD45A, MDK,
SERPINE1, TNFRSF10B) was identified. In addition, gene expression analysis was
done in C57BL/6 mice at doses 0-8 Gy and times 5, 12, 23 and 48 hours after
irradiation. The results showed a significant increase in the expression of five of the
above genes (BBC3, CCNG1, CDKN1A, SERPINE1 and TNFRSF10B) (10).
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This article focuses on gene expression analysis of Drosophila melanogaster (fruit
flies). Compared to humans, biodosimetry information can be obtained in a more
controlled manner in animal models because the dose received in humans are usually
not known, the exposures may be non uniform and the dose rates may not be known.
Data collection may not be reliable and uniform post irradiation because a lot of
variables have to be taken into consideration like age, health, sex, genotype, time
since exposure to radiation, personal lifestyle like cigarette smoking, tobacco and
alcohol habits (5, 17). Drosophila melanogaster is a model organism with a useful
lifespan ( ̴ 2 months) and a long history in radiation experiments. Its genome has been
sequenced, and many genes in Drosophila are homologous with human genes (18, 19).
This article makes use of a previous gene expression analysis done by Antosh et al.
(2014). The experiment was performed in order to discover the biological effects at
different levels of ionizing radiation in D.

melanogaster. The results showed a

threshold effect in response to the radiation, both in gene expression and in survival.
The gene expression results suggest stress, metabolism, reproduction and
mitochondrial function as mechanisms involved in the radiation response (20). The
data was taken for five radiation doses (plus a control), at 3 time points. The setup of
this data allows it to be repurposed for a new analysis that examines the response of
genes as a function of radiation dose.
The aim of this study is to secure a set of genes that are responsive to radiation in a
predictable way. These genes, particularly if homologous to human genes, have
potential uses in radiation dosimetry.
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Methodology
The data used in this paper is obtained from data submitted to the gene expression
omnibus by Antosh et al (posted under the reference number GSE47999). Normalized
data was calculated using the DESeq (21) package in Bioconductor (22).
The data was obtained from an RNA-sequencing gene expression experiment on
drosophila melanogaster. at ages 2, 10 and 20 days after irradiating them Flies were
irradiated with x-ray exposures of 0, 10, 1000, 5000, 10000 and 20000 roentgen (a 1
roentgen radiation exposure is ≈ 0.01 gray; here we will use the terms “exposure” and
“dose” equivalently). The irradiation came inside a chamber containing cesium-137.
Samples were taken at 2, 10 and 20 days after irradiation, with 3 samples per
experimental condition (except for sample for 0R, Day 20, where one sample failed
quality check). Our re-analysis of this data was done to identify the genes that
changed in a predictable way from control, as a function of dose. Genes that behave in
a predictable way could potentially be used in a future bio dosimeter.
The fold changes in the expression of genes depending on dose and time after
exposure were measured in the fruit fly model. To calculate the fold change, average
value of the gene expression of the samples at each time point and radiation dose was
divided by the average value of gene expression of control at the same time point
(control being zero added radiation). Fold changes were ignored (in a present/absent
cutoff) if the average expression in both experimental and control samples was less
than a bottom quartile cutoff ( ~18-20 counts).
One analysis performed was based on linear regression. For each time point, the R2
value for a linear fit to (fold change vs. radiation dose) was calculated for each gene.
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Genes with R2>0.9 were selected as behaving linearly. In a secondary analysis, the
data for 10 R flies was removed (since this is a very small dose of radiation for fruit
flies). The linear analysis described above was run again. In both of these analyses,
genes were only selected as linear if at least four radiation doses passed the
present/absent cutoff (described in the paragraph immediately before this).
As an additional analysis, gene expression data was examined for “spikes” in fold
change. For each gene, at each time point, a set of fold changes was examined (one
fold change for each radiation dose). Genes were marked as having a spike if the
largest fold change was at least five times greater than the second largest fold change.
Additionally, genes were only counted as having a spike if the fold change of the spike
was > 1 (meaning that the average expression at the spike dose was greater than
average gene expression in the corresponding control).
For each time point, and for overlaps between time points, genes found to be
significant (meaning, linear or spiking) were analyzed as a group using GOStat (23) to
see if any biological functions were had a statistically significant amount of genes in
the group. Gene ontologies with a corrected p value < 0.05 were selected.
Genes were examined for human homologues using homologene (19) and functional
information was found using flybase (18).

Results
Analysis of Linear Behavior with Full Dataset
Figure 1 shows the number of genes with a linear response in fold change as a
function of radiation dose, at each of the three time points (2, 10 and 20 days
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postirradiation). Seventy-eight genes showed a linear response at day 2 after
irradiation; 677 genes showed a linear response at day 10 after irradiation; 432 genes
showed linear response at day 20 after irradiation. A set of 6 genes (FBgn0011774,
FBgn0030189, FBgn0031713, FBgn0032393, FBgn0037020, and FBgn0051864) was
found to have a linear response in all time points. Table 1 shows the set of those 6
genes, including homology to human genes (19) and functional information (18). 4 out
of these 6 genes have homologues in humans. Genes found to behave linearly across a
fairly wide range of times are perhaps most promising for a possible radiation
dosimeter. The median lifespan of control flies in this experiment was ̴ 50 days; our
time range here is 18 days.
A GOStat analysis (23) was run on genes found to be linear at each time point, and
also separately on overlaps between time points. Full lists of significant gene
ontologies from the analysis can be found in Supplemental Table S1A-1G. Several of
the results suggest that the genes that behave linearly are involved in stress responses.
At 2 days postirradiation, 78 genes show linear behavior with dose. These 78 genes
contain 13 out of the 23 genes related to protein kinase CK2 regulator activity (a p
value of 2.2X10-24). The protein kinase CK2 inhibits apoptosis following ionizing
radiation (24). Gene ontologies for spermatogenesis and reproduction are also affected
2 days postirradiation. Genes found to be linear at 10 days postirradiation were
statistically over representative of gene ontologies for oxidoreductase activity (a
possible response to radiation damage) and growth factor activity. At 20 days
postirradiation, overrepresented gene ontologies included stress-related pathways such
as response to stress, receptor activity, signal transducer activity, detection of

78

bacterium and biotic stimulus and response to DNA damage stimulus. In the genes
found in the overlap of day 2 and day 10, overrepresented gene ontologies included
peroxisomal transport and NADPH activity. In the genes found in the overlap of day 2
and day 20, overrepresented gene ontologies included several pathways related to the
peroxisome, DNA helicase activity, response to hypoxia and telomere maintenance.
The overlap between genes in days 10 and 20 found the gene ontology for stress
response to be overrepresented. Gene ontologies overrepresented in genes found to be
linear at all three time points (2, 10 and 20 days) included peroxisome, DNA helicase
activity, ATPase activity and telomere maintenance.

Analysis of Linear Behavior with Lowest Dose Not Included
In the lifespan experiment that accompanied this dataset (20), lifespan effects on fruit
flies were not seen until a radiation exposure of 10,000 roentgen (an approximate
radiation dose of 100 Gy). The smallest dose in this analysis is 10 roentgen, which is
0.1% of that dose. It is possible that the 10 roentgen dose in this experiment may
produce some gene expression at the level of noise. To address that possibility, a
secondary analysis for linear behavior was run where the data from 10 roentgen were
not included. The results are summarized in figure 2. In this analysis, 13 genes are
found to be linear at all three time points. This list includes 5 of the 6 genes found to
behave linearly at all three data points when the 10 R data was included in the analysis
(Table 1). The 6th gene, FBgn0031713, was excluded only because R2 = 0.88 at day
20. The 13 genes in the overlap are described in Table 2. Of these 13 genes, 4 have
human homologues.
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A GOStat analysis (23) was run on genes found to be linear at each time point, and
also separately on overlaps between time points. Full lists of significant gene
ontologies from the analysis can be found in Supplemental Table 2A-2G. As with the
analysis with all radiation doses, several of the results suggest that the genes that
behave linearly are involved in stress responses.
At 2 days postirradiation, overrepresented gene ontologies include protein kinase CK2
regulator activity and spermatogenesis. Genes found to be linear at 10 days
postirradiation were statistically over representative of gene ontologies for
oxidoreductase activity (a possible response to radiation damage), growth factor
activity, GTPase activity, hydrolase activity, electron carrier activity and pathways
related to peroxisomes. At 20 days postirradiation, overrepresented gene ontologies
included detection of biotic stimulus and bacterium and metabolism of toxins,
xenobiotics, insecticide and water-soluble vitamins. In the genes found in the overlap
of day 2 and day 20, overrepresented gene ontologies included peroxisomal transport,
NADPH regeneration, telomere maintenance, DNA helicase activity, transferase
activity and ATPase activity. The overlap between genes in days 10 and 20 found
several gene ontologies related to peroxisomes to be overrepresented. Gene ontologies
overrepresented in genes found to be linear at all three time points (2, 10 and 20 days)
included pathways related to peroxisomes, telomere maintenance and Wnt signaling.
No gene ontologies were significantly overrepresented in the overlap between genes
linear at day 2 and day 10 postirradiation.
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Analysis of Genes for Spikes in Expression
In addition to linear behavior, another potential methodology for using gene
expression as a dosimeter would involve genes that “spike”; meaning that a given gene
sees a large amount of expression (compared to control flies) at a given radiation dose.
In order to search for such an effect in this dataset, we looked for genes where the fold
change was at least 5 times higher at one radiation dose than at any other radiation
dose examined. The results are shown in figure 3A, and in Supplemental Tables 3A-G
and 4A-G. Zero genes were found in the overlap between all three time points, which
suggests that there may be no good candidate genes for a biological dosimeter.
Similar to the linear analysis, we performed the analysis a second time with the data
for 10 roentgen radiation exposure removed. Results are shown in Figure 3B, and
Supplemental Table 4H-4N. In this analysis, one gene was found to be changing at all
three time points. This gene, FBgn0085364, has no human homologue and no listed
functions in Flybase (in Flybase, a search for this gene is directed towards
FBgn0267910).
For the spike analysis, GOStat analyses were run with the genes being separated by
the radiation dose where a spike is found. Any spikes at the largest radiation dose were
not considered, because it is likely that a highest expression value at the highest
radiation dose is indicative of a gene that is merely increasing with dose (not
necessarily in a linear fashion). The radiation doses at which each gene spikes are
listed in Supplemental Tables 3A-G and 4A-G. Overall, the GOStat results on spiking
genes showed an effect on reproduction and some effect on stress responses.
The analysis with all radiation doses included the following:
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For genes with spikes at day 2 postirradiation at radiation dose 5000 roentgen,
overrepresented gene ontologies are all due to FBgn0013745 and are related to
reproduction and behavior.



For genes with spikes at day 2 postirradiation at radiation dose 1000 R, the
only two genes are yolk protein 1 and yolk protein 2 (note: in this section, all
full gene names were found in Flybase). Overrepresented gene ontologies
include vitellogenesis, reproductive development and chromatin remodeling.



For genes with spikes at day 10 postirradiation, only five genes are not from
the highest radiation dose. These five genes are all from dose 10 R.
Overrepresented gene ontologies include those related to chorion (from
chorion protein 15 and chorion protein 18) and sensing of chemical stimulus
(from odorant binding protein 19c).



For genes with spikes at day 20 postirradiation, only one gene is not from the
highest radiation dose. This gene, FBgn53222, spiked at dose 5000 roentgen
and gave overrepresented gene ontologies related to ribosomes.

The analysis with the lowest radiation dose (10 roentgen) did not include the
following:


For genes with spikes at day 2 postirradiation, only four genes spiked at doses
less than the maximum dose. Two genes spiked at dose 5,000 R; all
overrepresented pathways in GOstat were due to FBgn0013745 (similar to the
analysis including 10 roentgen). Two genes spiked at dose 10,000 R – yolk
protein 1 (as in the analysis including 10 roentgen) and FBgn0013675, which
resulted in overrepresented gene ontologies related to oxidative response.
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For genes with spikes at day 10 postirradiation, seven genes spiked at dose
10,000 roentgen. Six of these seven genes were related to reproduction, and
include yolk proteins 1, 2 and 3.



For genes with spikes at day 20 postirradiation, one gene (FBgn0053222)
spiked at dose 5000 R (the same gene as the analysis including 10 roentgen).

GOstat results related to the results reported above can be found in Supplemental
Tables 5A-H.

Discussion
A radiation dosimeter based on gene expression could result in the better diagnosis of
radiation dose in patients, and thus may help in saving lives after a nuclear event or
accidental radiation exposure. The results of this paper indicate several candidate
genes that have potential to be used for that purpose. In particular, it seems that the
best candidates may be the genes listed in Tables 1 and 2 that have human
homologues.
One particularly interesting candidate gene is Irbp (inverted Repeat Binding Protein),
which was found to behave linearly in all three data points, both with the full data set
and with the lowest dose removed. Irbp is related to DNA repair. It is reasonable to
predict that DNA damage is linear with radiation dose; thus, it is logical that some
DNA repair genes may respond linearly in expression. Irbp has homologues in
organisms that are as complex as humans and chimpanzees, and also in organisms
such as Japanese rice (19).
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Another possibility, based on the application of GOstat results, is to look at particular
cellular functions. In particular, the function of protein kinase CK2 may be useful at
time points soon after radiation exposure. Protein kinase CK2 was overrepresented in
the GOstat analysis for genes found to behave linearly 2 days after irradiation, with a
very high statistical significance. Perhaps the functionality of this protein kinase could
be measured directly as a function of radiation to produce a different type of radiation
dosimeter.
Several genes listed in Tables 1 and 2 had no known functions in Flybase (18). These
results suggest that they are related to radiation responses, and possibly to stress
responses.
From a dose-response standpoint, one interesting characteristic of the linear analysis
results is that some genes with a linear response in fold change have fold changes that
are less than 1 (radiation expression less than control expression) at lower doses, but
then transition to fold changes greater than 1 (radiation expression greater than control
expression) at high doses. For example, in the linear analysis with all radiation doses
the genes FBgn0011774, FBgn0030189, FBgn0037020 and FBgn0051864 are linear
at all three time points and exhibit this behavior at day 2 postirradiation. Descriptions
of these genes can be found in table 1. This could be representative of some biological
effects being in one direction at lower doses of radiation, and in the opposite direction
at higher doses of radiation. Fold changes and R2 values are given in Supplemental
Tables 3A-3F.
Future questions related to this research could include:
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How well do results in Drosophila genes with human homologues translate to
results in humans?



Do the genes in Tables 1 and 2 continue to respond linearly at more times
postirradiation, including times < 2 days?



How are these results affected by the energy and type of irradiation?

Further development of this methodology is needed before it can be applied to
patients, but these results suggest the possibility of a successful gene expression
radiation dosimeter.
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Tables
Table 1. Name, homology and functional information on 6 genes found to
respond linearly to radiation at all time points examined.

Flybase ID

Gene Symbol
Chromosome(G
(from
ramates,
flybase)(Gramates
Marygold et al.
, Marygold et al.
2017)
2017)

Human Gene
Homolog (From
Homologene)2016

Biological
Function(Gramates,
Marygold et al. 2017)

Molecular
Function(Gramates,
Marygold et al. 2017)

Contributes to DNA
binding, protein
heterodimerization activity,
ATP-dependent,ATPdependent DNA helicase
activity,damage DNA
binding,Telomeric DNA
binding inferred

FBgn0011774

3R

Irbp

XRCC6

Double-strand break
repair via
nonhomologous end
joining, telomere
maintenence

FBgn0030189

X

CG2909

none

Not known

Not known

COQ6

Oxidation reduction
process,Ubiquinone
biosynthetic process

FAD
binding,Oxidoreductase
activity, acting on paired
donors, with incorporation
or reduction of molecular
oxygen, NAD(P)H as one
donor, and incorporation of
one atom of oxygen

NFS1

Alanine biosynthetic
process, Iron-sulfur,
cluster assembly,[2Fe2S] cluster assembly

Cystathionine gamma-lyase
activity, Cysteine
desulfurase
activity,Pyridoxal
phosphate binding

Receptor binding

Not known

FBgn0031713

FBgn0032393

2L

2L

CG7277

CG12264

FBgn0037020

3L

Pex14

PEX14

Peroxisome
organization,Protein
import into peroxisome
matrix,docking,Protein
targeting to peroxisome

FBgn0051864

2L

Qtzl

none

Not known
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Table 2. Genes found to behave linearly at all three time points, if the lowest radiation
dose (10 R) is not included. Name, homology and functional information on 13 genes
found to respond linearly to radiation at all time points examined.

Flybase ID

Gene
Chromosome(Gra
Symbol(Gramates
mates, Marygold
, Marygold et al.
et al. 2017)
2017)

Human Gene
Homologue (2016)

Biological Function
Molecular Function
(Gramates, Marygold et al. (Gramates, Marygold et al.
2017)
2017)

Double-strand break repair
via nonhomologous end
DNA binding,Protein
joining, telomere
heterodimerization activity
maintenance

FBgn0011774

3R

Irbp

XRCC6

FBgn0024912

3R

agt

none

DNA dealkylation involved
in DNA repair

Methylated-DNA-[protein]cysteine Smethyltransferase activity

FBgn0027101

4

Dyrk3

DYRK2

Protein phosphorylation

ATP binding, Protein

FBgn0030189

X

CG2909

none

Not known

Not known
Cystathionine gammalyase activity,Cysteine
desulfurase
activity,Pyridoxal
phosphate binding

FBgn0032393

2L

CG12264

NFS1

Alanine biosynthetic
process,Iron-sulfur cluster
assembly,[2Fe-2S] cluster
assembly

FBgn0033926

2R

Arc1

none

Behavioral response to
starvation,Muscle system
process

Not known

FBgn0033927

2R

CR10102

none

Not known

Not known

FBgn0034184

2R

CG9646

none

Not known

Not known

FBgn0036290

3L

CG10638

none

Oxidation – reduction
process inferred

Oxidoreductase activity,
inferred

FBgn0037020

3L

Pex14

PEX14

Peroxisome organization,

Not known

FBgn0037850

3R

CG14695

none

Not known

Not known

FBgn0046763

3R

CG17278

none

Negative regulation of Wnt
signaling pathway inferred
from genetic interaction

Not known

FBgn0051864

2L

Qtzl

none

Not known

Not known
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Figures

Figure 1. . Number of genes with linear response at each time point, with overlaps

91

Figure 2. Analysis of linear behavior, not including data from dose 10 Roentgen.
Number of genes with linear response (R2 > 0.9) are given for each time point, with
overlaps.

92

Figure 3. Number of “spike” genes at each time point, with (3A) and without (3B) the
lowest radiation dose.

93

Supplementary Tables

GO

Count Total P Value GO Name

GO:0008605 13

23

2.21E-24 protein kinase CK2 regulator activity

GO:0005956 13

23

2.21E-24 protein kinase CK2 complex

GO:0043549 12

35

2.19E-19 regulation of kinase activity

GO:0051338 12

35

2.19E-19 regulation of transferase activity

GO:0045859 12

35

2.19E-19 regulation of protein kinase activity

GO:0019887 13

53

5.02E-19 protein kinase regulator activity

GO:0019207 13

55

7.39E-19 kinase regulator activity

GO:0050790 12

57

1.10E-16 regulation of catalytic activity

GO:0065009 12

70

1.41E-15 regulation of a molecular function

GO:0007283 10

150

1.13E-08 spermatogenesis

GO:0048232 10

150

1.13E-08 male gamete generation

GO:0043234 19

1371 8.22E-08 protein complex

GO:0032991 20

1652 1.45E-06 macromolecular complex

GO:0007276 11

704

0.00244 gamete generation

GO:0019953 11

730

0.00307 sexual reproduction

GO:0065007 15

1459 0.00307 biological regulation

GO:0044464 30

4358 0.00372 cell#cell part

GO:0005623 30

4358 0.00372 cell

GO:0005737 16

1833 0.0213

cytoplasm

GO:0044459 6

305

0.0303

plasma membrane part

GO:0035147 2

14

0.0311

branch fusion, open tracheal system

GO:0035146 2

14

0.0311

branching morphogenesis of a tube#tube fusion

GO:0005634 13

1420 0.0416

nucleus

Table S1A. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Day 2 Post-Irradiation. (Analysis with all data included.)
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GO

Count

Total

P Value

GO Name

GO:0008083

6

17

0.0333

growth factor activity

GO:0016491

38

541

0.0333

oxidoreductase activity

Table S1B. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Day 10 Post-Irradiation. (Analysis with all data included.)

GO

Count

Total

P Value

GO Name

GO:0016021

33

608

0.00106

integral to membrane

GO:0031224

33

613

0.00106

intrinsic to membrane

GO:0016020

58

1367

0.0016

membrane

GO:0006950

15

211

0.0069

response to stress

GO:0044459

19

305

0.0069

plasma membrane part

GO:0005887

14

169

0.0115

integral to plasma membrane

GO:0044425

43

1002

0.0115

membrane#membrane part

GO:0031226

14

172

0.0115

intrinsic to plasma membrane

GO:0004872

23

424

0.0115

receptor activity

GO:0004888

20

355

0.0139

transmembrane receptor activity

GO:0004871

26

517

0.0139

signal transducer activity

GO:0060089

26

517

0.0139

molecular transducer activity

GO:0009595

3

5

0.0139

detection of biotic stimulus

GO:0016045

3

5

0.0139

detection of bacterium

GO:0030425

4

12

0.0139

dendrite

GO:0006281

8

67

0.0164

DNA repair

GO:0001871

6

36

0.0164

pattern binding

GO:0042834

4

13

0.0164

peptidoglycan binding

GO:0000270

3

7

0.0353

peptidoglycan metabolic process

GO:0006974

8

79

0.0448

response to DNA damage stimulus

Table S1C. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Day 20 Post-Irradiation. (Analysis with all data included.)
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GO

Count

Total

P Value

GO Name

GO:0004123

1

2

0.0243

cystathionine gamma-lyase activity

GO:0006625

1

2

0.0243

protein targeting to peroxisome

GO:0016226

1

2

0.0243

iron-sulfur cluster assembly

GO:0043574

1

2

0.0243

peroxisomal transport

GO:0031163

1

2

0.0243

metallo-sulfur cluster assembly

GO:0004090

1

3

0.0331

carbonyl reductase (NADPH) activity

Table S1D. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Days 2 and 10 Post-Irradiation. (Analysis with all data included.)

GO

Count

Total

P Value

GO Name

GO:0006950

9

211

0.00111

response to stress

Table S1E. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Days 10 and 20 Post-Irradiation. (Analysis with all data included.)
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GO

Count

Total

P Value

GO Name

GO:0004123

1

2

0.00745

cystathionine gamma-lyase activity

GO:0006625

1

2

0.00745

protein targeting to peroxisome

GO:0016226

1

2

0.00745

iron-sulfur cluster assembly

GO:0043574

1

2

0.00745

peroxisomal transport

GO:0031163

1

2

0.00745

metallo-sulfur cluster assembly

GO:0016846

1

6

0.0206

carbon-sulfur lyase activity

GO:0001666

1

9

0.0268

response to hypoxia

GO:0032200

1

10

0.0268

telomere organization and biogenesis

GO:0000723

1

10

0.0268

telomere maintenance

GO:0044439

1

12

0.0268

peroxisomal part

GO:0044438

1

12

0.0268

microbody#microbody part

GO:0031903

1

12

0.0268

microbody membrane

GO:0005778

1

12

0.0268

peroxisomal membrane

GO:0007031

1

13

0.0276

peroxisome organization and biogenesis

GO:0008652

1

20

0.0388

amino acid biosynthetic process

GO:0004003

1

20

0.0388

ATP-dependent DNA helicase activity

Table S1F. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Days 2 and 20 Post-Irradiation. (Analysis with all data included.)
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GO

Count

Total P Value

GO Name

GO:0004123

1

2

0.00517

cystathionine gamma-lyase activity

GO:0006625

1

2

0.00517

protein targeting to peroxisome

GO:0016226

1

2

0.00517

iron-sulfur cluster assembly

GO:0043574

1

2

0.00517

peroxisomal transport

GO:0031163

1

2

0.00517

metallo-sulfur cluster assembly

GO:0016846

1

6

0.0141

carbon-sulfur lyase activity

GO:0032200

1

10

0.0182

telomere organization and biogenesis

GO:0000723

1

10

0.0182

telomere maintenance

GO:0044439

1

12

0.0182

peroxisomal part

GO:0044438

1

12

0.0182

microbody#microbody part

GO:0031903

1

12

0.0182

microbody membrane

GO:0005778

1

12

0.0182

peroxisomal membrane

GO:0007031

1

13

0.0187

peroxisome organization and biogenesis

GO:0008652

1

20

0.0258

amino acid biosynthetic process

GO:0004003

1

20

0.0258

ATP-dependent DNA helicase activity

GO:0008094

1

29

0.0331

DNA-dependent ATPase activity

GO:0042579

1

31

0.0331

microbody

GO:0005777

1

31

0.0331

peroxisome

GO:0009309

1

34

0.0331

amine biosynthetic process

GO:0044271

1

35

0.0331

nitrogen compound biosynthetic process

GO:0043231

3

2283

0.0331

intracellular membrane-bound organelle

GO:0043227

3

2287

0.0331

membrane-bound organelle

GO:0003678

1

36

0.0331

DNA helicase activity

Table S1G: Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Days 2, 10 and 20 Post-Irradiation. (Analysis with all data included.)
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GO

Count

Total

P Value

GO Name

GO:0008605

13

23

5.14E-13

xprotein kinase CK2 regulator activity

GO:0005956

13

23

5.14E-13

protein kinase CK2 complex

GO:0043549

12

35

4.92E-09

regulation of kinase activity

GO:0051338

12

35

4.92E-09

regulation of transferase activity

GO:0045859

12

35

4.92E-09

regulation of protein kinase activity

GO:0019887

13

53

6.60E-08

protein kinase regulator activity

GO:0019207

13

55

9.35E-08

kinase regulator activity

GO:0050790

12

57

1.63E-06

regulation of catalytic activity

GO:0065009

13

70

1.72E-06

regulation of a molecular function

GO:0007283

17

150

1.68E-05

xspermatogenesis

GO:0048232

17

150

1.68E-05

male gamete generation

GO:0022411

5

13

0.00115

cellular component disassembly

Table S2A. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Day 2 Post-Irradiation. (Analysis with lowest dose discluded.)
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GO

Count Total P Value GO Name

GO:0003924 17

102 0.0028 GTPase activity

GO:0016798 16

102 0.0118 hydrolase activity, acting on glycosyl bonds

GO:0005102 19

136 0.0129 receptor binding

GO:0004553 15

96

GO:0009055 21

166 0.0282 electron carrier activity

GO:0005624 14

93

GO:0005515 79

974 0.0334 protein binding

GO:0000267 14

96

GO:0016740 70

851 0.0411 transferase activity

GO:0008083 6

17

0.0411 growth factor activity

GO:0005778 5

12

0.0427 peroxisomal membrane

GO:0044438 5

12

0.0427 microbody#microbody part

GO:0031903 5

12

0.0427 microbody membrane

GO:0044439 5

12

0.0427 peroxisomal part

GO:0016491 48

541 0.0499 oxidoreductase activity

0.0129 hydrolase activity, hydrolyzing O-glycosyl compounds

0.0334 membrane fraction

0.0411 cell fraction

Table S2B. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Day 10 Post-Irradiation. (Analysis with lowest dose discluded.)
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GO

Count Total P Value GO Name

GO:0005887

16

169

0.0205

integral to plasma membrane

GO:0031226

16

172

0.0205

intrinsic to plasma membrane

GO:0000270

4

7

0.0205

peptidoglycan metabolic process

GO:0042834

5

13

0.0205

peptidoglycan binding

GO:0017143

4

9

0.0328

insecticide metabolic process

GO:0006805

4

9

0.0328

xenobiotic metabolic process

GO:0009404

4

9

0.0328

toxin metabolic process

GO:0009410

4

9

0.0328

response to xenobiotic stimulus

GO:0016020

70

1367 0.0355

membrane

GO:0046903

15

172

0.0361

secretion

GO:0019752

14

156

0.0361

carboxylic acid metabolic process

GO:0006082

14

156

0.0361

organic acid metabolic process

GO:0009056

15

174

0.037

catabolic process

GO:0044459

22

305

0.0377

plasma membrane part

GO:0016192

26

386

0.0377

vesicle-mediated transport

GO:0006767

4

11

0.0377

water-soluble vitamin metabolic process

GO:0009595

3

5

0.0377

detection of biotic stimulus

GO:0016045

3

5

0.0377

detection of bacterium

GO:0030425

4

12

0.0486

dendrite

GO:0016021

36

608

0.0486

integral to membrane

Table S2C. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Day 20 Post-Irradiation. (Analysis with lowest dose discluded.)
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(none)

Table S2D. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Days 2 and 10 Post-Irradiation. (Analysis with lowest dose discluded.)

GO

Count Total P Value GO Name

GO:0005778

3

12

0.0165

peroxisomal membrane

GO:0044438

3

12

0.0165

microbody#microbody part

GO:0044439

3

12

0.0165

xperoxisomal part

GO:0031903

3

12

0.0165

microbody membrane

GO:0007031

3

13

0.0171

peroxisome organization and biogenesis

Table S2E. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Days 10 and 20 Post-Irradiation. (Analysis with lowest dose discluded.)
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GO

P Value

GO Name

GO:0000723 2

Count Total
10

0.0169

telomere maintenance

GO:0032200 2

10

0.0169

telomere organization and biogenesis

GO:0004003 2

20

0.0217

GO:0016772 5

446

0.0217

ATP-dependent DNA helicase activity
transferase activity, transferring
phosphorus-containing groups

GO:0008094 2

29

0.0217

GO:0043296 2

36

0.0217

DNA-dependent ATPase activity
apicolateral plasma membrane#apical
junction complex

GO:0003678 2

36

0.0217

DNA helicase activity

GO:0016740 6

851

0.0217

transferase activity

GO:0016327 2

40

0.0237

apicolateral plasma membrane

GO:0005911 2

50

0.0302

intercellular junction

GO:0006081 1

2

0.0302

aldehyde metabolic process

GO:0004105 1

2

0.0302

choline-phosphate cytidylyltransferase activity

GO:0031163 1

2

0.0302

metallo-sulfur cluster assembly

GO:0004345 1

2

0.0302

glucose-6-phosphate dehydrogenase activity

GO:0004123 1

2

0.0302

cystathionine gamma-lyase activity

GO:0006625 1

2

0.0302

protein targeting to peroxisome

GO:0016226 1

2

0.0302

iron-sulfur cluster assembly

GO:0043574 1

2

0.0302

peroxisomal transport

GO:0016337 2

59

0.0361

GO:0017116 1

3

0.0415

cell-cell adhesion
single-stranded DNA-dependent ATP-dependent DNA
helicase activity

GO:0043142 1

3

0.0415

single-stranded DNA-dependent ATPase activity

GO:0016779 2

68

0.0438

nucleotidyltransferase activity

GO:0008026 2

70

0.0443

ATP-dependent helicase activity

GO:0051186 2

75

0.0443

cofactor metabolic process

GO:0030054 2

75

0.0443

cell junction

GO:0006740 1

4

0.0443

NADPH regeneration

GO:0009225 1

4

0.0443

nucleotide-sugar metabolic process

GO:0006098 1

4

0.0443

pentose-phosphate shunt

GO:0006739 1

4

0.0443

GO:0005923 1

4

0.0443

GO:0016616 2

79

0.0471

NADP metabolic process
apicolateral plasma membrane#apical junction
complex#tight junction
oxidoreductase activity, acting on the CH-OH group
of donors, NAD or NADP as acceptor

Table S2F. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Days 2 and 20 Post-Irradiation. (Analysis with lowest dose discluded.)
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GO

Count Total P Value

GO Name

GO:0004123

1

2

0.0123

cystathionine gamma-lyase activity

GO:0006625

1

2

0.0123

protein targeting to peroxisome

GO:0006081

1

2

0.0123

aldehyde metabolic process

GO:0016226

1

2

0.0123

iron-sulfur cluster assembly

GO:0043574

1

2

0.0123

xperoxisomal transport

GO:0031163

1

2

0.0123

metallo-sulfur cluster assembly

GO:0004032

1

6

0.0323

aldehyde reductase activity

GO:0016846

1

6

0.0323

carbon-sulfur lyase activity

GO:0004033

1

8

0.0405

aldo-keto reductase activity

GO:0004674

2

190

0.0412

protein serine/threonine kinase activity

GO:0032200

1

10

0.0412

telomere organization and biogenesis

GO:0000723

1

10

0.0412

xtelomere maintenance

GO:0030178

1

11

0.0412

xnegative regulation of Wnt receptor signaling pathway

GO:0044439

1

12

0.0412

peroxisomal part

GO:0044438

1

12

0.0412

microbody#microbody part

GO:0031903

1

12

0.0412

microbody membrane

GO:0005778

1

12

0.0412

peroxisomal membrane

GO:0007031

1

13

0.0429

peroxisome organization and biogenesis

Table S2G. Gene Ontologies Overrepresented in Genes Found to Behave Linearly at
Days 2, 10 and 20 Post-Irradiation. (Analysis with lowest dose discluded.)
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Day
2 Day
2 Day
2 Day
2
Fold
Fold
Fold
Fold
Day 2 Fold
Change Change Change Change Change
10R
1000R
50000R 10000R 20000R

Flybase ID

Spike
Ratio

Dose
Causing
Spike

FBgn0005391

6.018

10000R

2.573

0.888

0.545

15.486

1.268

FBgn0004045

15.787

10000R

0.936

0.447

0.849

16.168

1.024

FBgn0038191

5.379

1000R

0.248

1.332

0.141

0.183

0.154

FBgn0013672

7.952

20000R

1.114

0.656

0.783

0.651

8.855

FBgn0013678

7.046

20000R

1.028

0.774

0.681

0.729

7.242

FBgn0034152

6.826

20000R

0.780

6.282

2.196

6.885

46.999

FBgn0013676

6.461

20000R

1.278

0.876

1.026

0.772

8.256

FBgn0013674

6.025

20000R

1.271

1.155

0.874

0.985

7.656

FBgn0259968

5.361

20000R

0.945

1.163

0.673

0.789

6.237

FBgn0013675

13.108

20000R

1.336

0.673

0.855

0.522

17.518

FBgn0013745

7.176

5000R

0.371

0.966

11.772

1.155

1.640

FBgn0262099

6.609

5000R

0.591

5.446

44.237

6.693

5.023

Table S3A. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day
2 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest fold
change)/(second largest fold change)
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Flybase ID

Dose
SpikeRa Causing
tio
Spike

Day10
Fold
Change
10R

Day10
Fold
Change
1000R

Day10
Fold
Change
5000R

Day10
Day10 Fold Fold
Change
Change
10000R
20000R

FBgn0013679 9.785

20000R

2.051

1.087

1.137

1.197

20.065

FBgn0025740 9.617

20000R

0.429

0.708

0.469

0.462

6.805

FBgn0013672 9.472

20000R

0.758

0.864

1.744

0.981

16.520

FBgn0085364 9.183

20000R

1.107

1.655

1.378

1.306

15.201

FBgn0013676 8.690

20000R

0.921

0.799

1.255

1.007

10.907

FBgn0031111 8.280

10R

13.211

1.114

1.485

1.011

1.596

FBgn0013681 7.360

20000R

1.370

0.709

1.617

0.388

11.902

FBgn0000427 68.582

20000R

164.035

1.051

1.101

1.066

2.392

FBgn0259968 6.846

20000R

1.012

1.200

1.482

1.239

10.143

FBgn0041709 6.434

10R

24.479

0.793

0.771

1.388

3.805

FBgn0013686 6.416

20000R

0.563

0.882

0.650

0.863

5.657

FBgn0021738 6.346

20000R

0.478

0.673

0.860

0.708

5.455

FBgn0262972 6.089

20000R

0.770

0.886

0.821

0.256

5.397

FBgn0000357 52.726

10R

76.612

0.932

1.159

1.218

1.453

FBgn0039916 5.769

20000R

0.351

0.749

1.016

0.939

5.862

FBgn0037836 5.715

20000R

0.869

1.050

1.071

0.741

6.122

FBgn0036790 5.703

20000R

0.355

0.705

0.575

0.469

4.018

FBgn0036985 5.546

20000R

0.568

1.104

0.578

0.905

6.126

FBgn0032946 5.427

20000R

1.689

1.590

1.541

1.264

9.167

FBgn0086782 5.393

20000R

0.684

0.802

0.592

0.965

5.205

FBgn0052350 5.357

20000R

0.610

0.803

0.900

1.126

6.034

FBgn0013675 5.229

20000R

0.857

0.937

2.220

0.813

11.611

FBgn0039925 35.389

20000R

0.305

0.413

0.446

0.518

18.324

FBgn0013680 28.243

20000R

1.126

1.065

1.218

0.802

34.413

FBgn0053855 21.401

20000R

2.643

0.651

0.897

2.320

56.555

FBgn0053858 21.234

20000R

2.791

0.722

0.928

2.390

59.260

FBgn0053810 20.386

20000R

2.449

0.632

0.869

1.988

49.934

FBgn0053831 19.800

20000R

2.574

0.582

0.855

1.974

50.972

FBgn0053837 19.797

20000R

2.442

0.651

0.838

1.921

48.348

FBgn0053822 19.649

20000R

2.621

0.607

0.794

2.017

51.495

FBgn0053816 19.527

20000R

2.529

0.583

0.874

1.958

49.377

FBgn0053861 19.524

20000R

3.118

0.737

0.932

2.407

60.868
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FBgn0053819 19.465

20000R

2.609

0.640

0.853

2.004

50.776

FBgn0053807 19.436

20000R

2.337

0.593

0.804

1.836

45.416

FBgn0053828 19.260

20000R

2.519

0.617

0.848

1.931

48.524

FBgn0053825 19.255

20000R

2.568

0.628

0.829

1.966

49.449

FBgn0053843 19.255

20000R

2.712

0.715

0.846

1.989

52.223

FBgn0053864 19.048

20000R

2.565

0.597

0.861

1.925

48.861

FBgn0053852 19.034

20000R

2.534

0.624

0.825

1.921

48.235

FBgn0053813 18.977

20000R

2.776

0.680

0.875

2.202

52.672

FBgn0053846 18.904

20000R

2.613

0.603

0.845

1.988

49.390

FBgn0051617 18.804

20000R

2.440

0.540

0.811

1.893

45.879

FBgn0053801 18.653

20000R

2.549

0.612

0.815

1.928

47.551

FBgn0053849 18.323

20000R

2.771

0.623

0.858

1.975

50.782

FBgn0053840 17.922

20000R

2.677

0.660

0.830

1.901

47.978

FBgn0053804 17.761

20000R

2.622

0.601

0.851

1.913

46.573

FBgn0013678 15.720

20000R

0.806

0.784

1.009

0.988

15.862

FBgn0000355 141.389 10R

130.305

0.922

0.687

0.127

0.165

FBgn0013685 14.707

20000R

1.367

0.670

0.853

0.396

20.105

FBgn0052602 13.143

10R

20.045

0.874

0.626

0.624

1.525

FBgn0052580 124.695 20000R

0.208

0.620

0.240

0.751

93.597

FBgn0013674 12.216

20000R

0.910

0.963

0.947

1.071

13.085

FBgn0262952 12.152

20000R

1.639

1.050

0.703

1.111

19.912

FBgn0013684 11.816

20000R

1.266

0.696

0.642

0.729

14.954

Table S3B. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day
10 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest fold
change)/(second largest fold change)
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Flybase ID

Dose
Spike Causing
Ratio Spike

Day 20
Fold
Change
10R

Day 20
Fold
Change
1000R

Day 20
Fold
Change
5000R

Day 20
Fold
Change
10000R

Day 20
Fold
Change
20000R

FBgn0053222

9.209 5000R

1.164

1.180

10.869

0.146

0.026

FBgn0085364

8.050 20000R

1.094

1.610

0.895

1.364

12.963

FBgn0039480

6.902 20000R

0.158

0.105

0.090

0.173

1.193

FBgn0040637

6.835 20000R

1.457

1.511

2.097

NA

14.334

Table S3C. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day
20 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest fold
change)/(second largest fold change)
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FlyBase
ID

Day Day
Spik
Day 2
2
e
Dose Spik Dose 2
Fold Fold
Rati Causi eRat Causi Fold Cha Cha
o
ng
io
ng
Cha nge nge
Day Spike Day1 Spike nge 100 5000
2
Day2 0
Day10 10R 0R 0R

Day
2
Day 2
Fold Fold Day1 Day10
Chan Chang 0 Fold Fold
ge
e
Chan Chang
1000 20000 ge
e
0R R
10R 1000R

Day10
Day10 Fold
Fold Chang
Chang e
e
10000
5000R R

Day10
Fold
Chang
e
20000
R

FBgn0013 7.95 20000
20000 1.11 0.65 0.78
672
2
R
9.472 R
4
6
3
0.651 8.855 0.758 0.864 1.744 0.981

16.520

FBgn0013 7.04 20000
20000 1.02 0.77 0.68
678
6
R
8.690 R
8
4
1
0.729 7.242 0.921 0.799 1.255 1.007

10.907

FBgn0013 6.46 20000
20000 1.27 0.87 1.02
676
1
R
6.846 R
8
6
6
0.772 8.256 1.012 1.200 1.482 1.239

10.143

FBgn0013 6.02 20000
20000 1.27 1.15 0.87
674
5
R
5.229 R
1
5
4
0.985 7.656 0.857 0.937 2.220 0.813

11.611

FBgn0259 5.36 20000
20000 0.94 1.16 0.67
968
1
R
15.72 R
5
3
3
0.789 6.237 0.806 0.784 1.009 0.988

15.862

FBgn0013 13.1 20000 12.21 20000 1.33 0.67 0.85
675
08 R
6
R
6
3
5
0.522 17.518 0.910 0.963 0.947 1.071

13.085

Table S3D. Values of Spike Ratio and Fold Changes for Genes Found to Spike at
Days 2 and 10 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest
fold change)/(second largest fold change)
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Flybase
ID

Dose
Spik Causi
eRat ng
io
Spike
Day Day1
10 0

Dose
Caus
Spik ing
eRat Spik
io e
Day Day2
20 0

Day1
Day
Day Day1 0
Day1 Day1 Day 20
10 0 Fold Fold 0 Fold 0 Fold 20
Fold
Fold Chan Chan Chan Chan Fold Chan
Cha ge
ge
ge
ge
Chan ge
nge 1000 5000 10000 20000 ge
1000
10R R
R
R
R
10R R

Day Day
20
20
Fold Fold
Chan Chan
ge
ge
5000 10000
R
R

Day
20
Fold
Chan
ge
20000
R

FBgn0085 9.18 20000 8.05 2000 1.10
15.20
12.96
364
3
R
0
0R 7
1.655 1.378 1.306 1
1.094 1.610 0.895 1.364 3

Table S3E. Values of Spike Ratio and Fold Changes for Genes Found to Spike at
Days 10 and 20 Post-Irradiation. (Analysis with all data included.) Spike ratio =
(largest fold change)/(second largest fold change)

(none)

Table S3F. Values of Spike Ratio and Fold Changes for Genes Found to Spike at
Days 2 and 20 Post-Irradiation. (Analysis with all data included.) Spike ratio = (largest
fold change)/(second largest fold change)

(none)

Table S3G. Values of Spike Ratio and Fold Changes for Genes Found to Spike at
Days 2, 10 and 20 Post-Irradiation. (Analysis with all data included.) Spike ratio =
(largest fold change)/(second largest fold change)
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Flybase ID

Day
2 Day
2
Dose
Fold
Fold
Day 2
SpikeRa Causing Change Change Change
tio
Spike
1000R
5000R
10000R

FBgn0013678

9.356

20000R 0.774

0.681

0.729

7.242

FBgn0013680

9.132

20000R 0.563

0.683

0.420

6.233

FBgn0013676

8.044

20000R 0.876

1.026

0.772

8.256

FBgn0013673

7.347

20000R 0.466

0.685

0.372

5.031

FBgn0013683

7.239

20000R 0.944

0.695

0.318

6.832

FBgn0013745

7.176

5000R

11.772

1.155

1.640

FBgn0034152

6.826

20000R 6.282

2.196

6.885

46.999

FBgn0013674

6.631

20000R 1.155

0.874

0.985

7.656

FBgn0262099

6.609

5000R

44.237

6.693

5.023

FBgn0013681

6.558

20000R 0.798

0.916

0.515

6.005

FBgn0013684

6.476

20000R 0.788

0.633

0.788

5.102

FBgn0013679

5.956

20000R 1.004

0.879

0.867

5.981

FBgn0085364

5.415

20000R 1.298

0.718

0.916

7.026

FBgn0259968

5.361

20000R 1.163

0.673

0.789

6.237

FBgn0013685

24.186

20000R 0.338

0.246

0.237

8.163

FBgn0013675

20.490

10000R 0.673

0.855

0.522

17.518

FBgn0004045

15.787

10000R 0.447

0.849

16.168

1.024

FBgn0013672

11.306

20000R 0.656

0.783

0.651

8.855

0.966

5.446

Fold Day 2 Fold
Change
20000R

Table S4A. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day
2 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio = (largest fold
change)/(second largest fold change)
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Flybase ID

Spike
Ratio

Day
10 Day
10 Day
10 Day
10
Dose
Fold
Fold
Fold
Fold
Causing Change Change
Change
Change
Spike
1000R
5000R
10000R
20000R

FBgn0004045

87.528

10000R 1.684

2.465

515.653

5.891

FBgn0260780

7.925

10000R 1.245

1.084

19.861

2.506

FBgn0002962

7.160

10000R 1.413

2.257

16.159

1.356

FBgn0003023

5.911

10000R 0.741

0.755

8.156

1.380

FBgn0004047

34.886

10000R 0.937

1.088

37.960

1.078

FBgn0004649

19.854

10000R 1.338

0.734

26.571

0.523

FBgn0005391

158.647 10000R 1.399

1.805

391.716

2.469

FBgn0025740

9.617

20000R 0.708

0.469

0.462

6.805

FBgn0013672

9.472

20000R 0.864

1.744

0.981

16.520

FBgn0085364

9.183

20000R 1.655

1.378

1.306

15.201

FBgn0013676

8.690

20000R 0.799

1.255

1.007

10.907

FBgn0013681

7.360

20000R 0.709

1.617

0.388

11.902

FBgn0259968

6.846

20000R 1.200

1.482

1.239

10.143

FBgn0013686

6.416

20000R 0.882

0.650

0.863

5.657

FBgn0262972

6.089

20000R 0.886

0.821

0.256

5.397

FBgn0032946

5.765

20000R 1.590

1.541

1.264

9.167

FBgn0037836

5.715

20000R 1.050

1.071

0.741

6.122

FBgn0036790

5.703

20000R 0.705

0.575

0.469

4.018

FBgn0086782

5.393

20000R 0.802

0.592

0.965

5.205

FBgn0052350

5.357

20000R 0.803

0.900

1.126

6.034

FBgn0013675

5.229

20000R 0.937

2.220

0.813

11.611

FBgn0039925

35.389

20000R 0.413

0.446

0.518

18.324

FBgn0013680

28.243

20000R 1.065

1.218

0.802

34.413

FBgn0053843

26.253

20000R 0.715

0.846

1.989

52.223

FBgn0053831

25.818

20000R 0.582

0.855

1.974

50.972

FBgn0053849

25.717

20000R 0.623

0.858

1.975

50.782

FBgn0053822

25.530

20000R 0.607

0.794

2.017

51.495

FBgn0053864

25.387

20000R 0.597

0.861

1.925

48.861

FBgn0053819

25.332

20000R 0.640

0.853

2.004

50.776

FBgn0053861

25.293

20000R 0.737

0.932

2.407

60.868

FBgn0053840

25.241

20000R 0.660

0.830

1.901

47.978

FBgn0053816

25.222

20000R 0.583

0.874

1.958

49.377

FBgn0053837

25.174

20000R 0.651

0.838

1.921

48.348

FBgn0053825

25.150

20000R 0.628

0.829

1.966

49.449

FBgn0053828

25.132

20000R 0.617

0.848

1.931

48.524

FBgn0053810

25.121

20000R 0.632

0.869

1.988

49.934

FBgn0053852

25.107

20000R 0.624

0.825

1.921

48.235
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FBgn0053846

24.838

20000R 0.603

0.845

1.988

49.390

FBgn0053858

24.791

20000R 0.722

0.928

2.390

59.260

FBgn0053807

24.743

20000R 0.593

0.804

1.836

45.416

FBgn0053801

24.666

20000R 0.612

0.815

1.928

47.551

FBgn0053855

24.373

20000R 0.651

0.897

2.320

56.555

FBgn0053804

24.341

20000R 0.601

0.851

1.913

46.573

FBgn0051617

24.233

20000R 0.540

0.811

1.893

45.879

FBgn0053813

23.919

20000R 0.680

0.875

2.202

52.672

FBgn0013684

20.510

20000R 0.696

0.642

0.729

14.954

FBgn0262952

17.927

20000R 1.050

0.703

1.111

19.912

FBgn0013679

16.768

20000R 1.087

1.137

1.197

20.065

FBgn0013678

15.720

20000R 0.784

1.009

0.988

15.862

FBgn0052580

124.695 20000R 0.620

0.240

0.751

93.597

FBgn0013674

12.216

0.947

1.071

13.085

20000R 0.963

Table S4B. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day
10 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio = (largest fold
change)/(second largest fold change)

Flybase ID

Dose
Spike Causing
Ratio Spike

Day 20 Day
20 Day
20 Day
20
Fold
Fold
Fold
Fold
Change Change Change
Change
1000R
5000R
10000R
20000R

FBgn0053222

9.209 5000R

1.180

10.869

0.146

0.026

FBgn0085364

8.050 20000R

1.610

0.895

1.364

12.963

FBgn0039480

6.902 20000R

0.105

0.090

0.173

1.193

Table S4C. Values of Spike Ratio and Fold Changes for Genes Found to Spike at Day
20 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio = (largest fold
change)/(second largest fold change)
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Dose
Causi
Spike ng
Ratio Spike
Flybase ID
Day2 Day2
10000
FBgn0004045 15.787 R
20000
FBgn0013672 11.306 R
20000
FBgn0013674 6.631 R
20000
FBgn0013675 20.490 R
20000
FBgn0013676 8.044 R
20000
FBgn0013678 9.356 R
20000
FBgn0013679 5.956 R
20000
FBgn0013680 9.132 R
20000
FBgn0013681 6.558 R
20000
FBgn0013684 6.476 R
20000
FBgn0085364 5.415 R
20000
FBgn0259968 5.361 R

Day Day
Day
2
2
Day 2 Day 2
10
Spik
Fold Fold Fold Fold
Fold
e
Dose Chan Chan Chang Chang Day 10 Chan
Ratio Causin ge
ge
e
e
Fold
ge
Day1 g Spike 1000 5000 10000 20000 Change 5000
0
Day10 R
R
R
R
1000R R
87.52
8
10000R 0.447 0.849 16.168 1.024 1.684 2.465

Day
10 Day 10
Fold Fold
Chan Chang
ge
e
1000 20000
0R R
515.6
53 5.891

9.472 20000R 0.656 0.783 0.651
12.21
6
20000R 1.155 0.874 0.985

8.855 0.864

1.744 0.981 16.520

7.656 0.963

0.947 1.071 13.085

5.229 20000R 0.673 0.855 0.522

17.518 0.937

2.220 0.813 11.611

8.690 20000R 0.876 1.026 0.772
15.72
0
20000R 0.774 0.681 0.729
16.76
8
20000R 1.004 0.879 0.867
28.24
3
20000R 0.563 0.683 0.420

8.256 0.799

1.255 1.007 10.907

7.242 0.784

1.009 0.988 15.862

5.981 1.087

1.137 1.197 20.065

6.233 1.065

1.218 0.802 34.413

7.360 20000R 0.798 0.916 0.515
20.51
0
20000R 0.788 0.633 0.788

6.005 0.709

1.617 0.388 11.902

5.102 0.696

0.642 0.729 14.954

9.183 20000R 1.298 0.718 0.916

7.026 1.655

1.378 1.306 15.201

6.846 20000R 1.163 0.673 0.789

6.237 1.200

1.482 1.239 10.143

Table S4D. Values of Spike Ratio and Fold Changes for Genes Found to Spike at
Days 2 and 10 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio =
(largest fold change)/(second largest fold change)
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Day
10
Dose
Fold
Spike Causi Spike Dose
Chan
Ratio ng
Ratio Causing ge
Day Spike Day Spike
1000
Flybase ID 10
Day 10 20
Day 20 R
FBgn008536
20000
4
9.183 R
8.050 20000R 1.655

Day
10
Day 10 Fold
Day 10 Fold Chan
Fold
Chang ge
Change e
20000
5000R 10000R R
15.20
1.378 1.306 1

Day
20
Fold
Chan
ge
1000
R

Day Day
20
20
Fold Fold
Chan Chan
ge
ge
5000 10000
R
R

Day
20
Fold
Chang
e
20000
R

1.610 0.895 1.364 12.963

Table S4E. Values of Spike Ratio and Fold Changes for Genes Found to Spike at
Days 10 and 20 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio =
(largest fold change)/(second largest fold change)

Flybase ID

Day
2
Dose
Dose Day 2 Fold
Causin
Causin Fold Cha
Spike g
Spike g
Chang nge
Ratio Spike Ratio Spike e
5000
Day 2 Day 2 Day 20 Day20 1000R R

20000
FBgn0085364 5.415 R
8.050

Day Day
Day 2 Day 2 Day 20
20
Fold Fold 20
Fold Fold
Chang Chang Fold Chan Cha
e
e
Chan ge
nge
10000 20000 ge
5000 1000
R
R
1000R R
0R

Day
20
Fold
Chan
ge
2000
0R

20000
0.71
1.36 12.96
R
1.298 8
0.916 7.026 1.610 0.895 4
3

Table S4F. Values of Spike Ratio and Fold Changes for Genes Found to Spike at
Days 2 and 20 Post-Irradiation. (Analysis with lowest dose discluded.) Spike ratio =
(largest fold change)/(second largest fold change)
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Spik Dose
e
Causi
Ratio ng
Day Spike
Flybase ID 2
Day 2

Dose
Spik Causi
eRat ng
io Spike
Day Day
10 10

Spik Dose
e
Causi
Rati ng
o
Spike
Day Day
20 20

Day
Da
2
Da
y
Fold Day Day y 2 Day Day Day Day Day Day 20
Cha 2 2 FC 10 10 10 10 20 20 FC
nge FC FC 20 FC FC FC FC FC FC 10
1000 500 100 00 100 500 100 200 100 5000 00
R 0R 00R 0R 0R 0R 00R 00R 0R R 0R

Da
y
20
FC
200
00
R

FBgn008536
20000 9.18 20000 8.05 20000 1.29 0.71 0.91 7.0 1.65 1.37 1.30 15.2 1.61 0.89 1.3 12.
4
5.415 R
3
R
0
R
8
8 6 26 5 8 6 01 0 5
64 963

Table S4G. Values of Spike Ratio and Fold Changes (FC) for Genes Found to Spike
at Days 2, 10 and 20 Post-Irradiation. (Analysis with lowest dose discluded.) Spike
ratio = (largest fold change)/(second largest fold change)
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GO

Count Total P Value GO Name

GO:0045434

1

7

0.00511 negative regulation of female receptivity, post-mating

GO:0007621

1

8

0.00511 negative regulation of female receptivity

GO:0048521

1

8

0.00511 negative regulation of behavior

GO:0046008

1

10

0.00511 regulation of female receptivity, post-mating

GO:0045924

1

16

0.00511 regulation of female receptivity

GO:0060180

1

16

0.00511 mating behavior#female mating behavior

GO:0060181

1

16

0.00511 female receptivity

GO:0045297

1

18

0.00511 post-mating behavior

GO:0050795

1

18

0.00511 regulation of behavior

GO:0005179

1

47

0.012

hormone activity

GO:0033057

1

69

0.0139

reproductive behavior in a multicellular organism

GO:0032504

1

81

0.0139

GO:0048609

1

81

0.0139

multicellular organism reproduction
multicellular organism reproduction#reproductive process in a
multicellular organism

GO:0007617

1

82

0.0139

mating behavior

GO:0051705

1

82

0.0139

behavioral interaction between organisms

GO:0019098

1

87

0.0139

reproductive behavior

GO:0007618

1

94

0.0141

mating

GO:0005102

1

136

0.0193

receptor binding

GO:0022414

1

203

0.0271

reproduction#reproductive process

GO:0051704

1

212

0.0271

multi-organism process

Table S5A. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 PostIrradiation at Dose 5000 R. (Analysis with all data included.)
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GO

Count Total P Value

GO Name

GO:0007296

2

8

1.81E-05 vitellogenesis

GO:0007548

2

57

0.000515 sex differentiation

GO:0003006

2

77

0.00063

GO:0007028

2

109

0.000951 cytoplasm organization and biogenesis

GO:0005811

2

129

0.00107

lipid particle

GO:0022414

2

203

0.00221

reproduction#reproductive process

GO:0016590

1

6

0.00584

ACF complex

GO:0005678

1

9

0.00767

chromatin assembly complex

GO:0007292

2

528

0.00999

female gamete generation

GO:0007276

2

704

0.0156

gamete generation

GO:0019953

2

730

0.0156

sexual reproduction

GO:0016585

1

33

0.0187

chromatin remodeling complex

reproductive developmental process

Table S5B. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 PostIrradiation at Dose 10,000 R. (Analysis with all data included.)

GO

Count Total P Value

GO Name

GO:0005213

2

9

8.52E-05

GO:0007306

2

64

0.00229

GO:0007304

2

88

0.00229

structural constituent of chorion
ovarian follicle cell development#chorioncontaining eggshell formation#eggshell chorion
formation
ovarian follicle cell development#chorioncontaining eggshell formation

GO:0030703

2

89

0.00229

eggshell formation

GO:0030707

2

184

0.00779

GO:0048646

2

235

0.0105

ovarian follicle cell development
anatomical structure development#anatomical
structure morphogenesis#anatomical structure
formation

GO:0048477

2

519

0.0385

oogenesis

GO:0007292

2

528

0.0385

female gamete generation

GO:0005549

1

54

0.0496

odorant binding

Table S5C. Overrepresented Gene Ontologies in Genes Found to Spike at Day 10
Post-Irradiation at Dose 10,000 R. (Analysis with all data included.)
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(none)

Table S5D. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 PostIrradiation at Dose 5000 R. (Analysis with all data included.)

GO
GO:0045434

Count Total P Value GO Name
negative regulation of female receptivity, post1
7
0.00511 mating

GO:0007621

1

8

0.00511 negative regulation of female receptivity

GO:0048521

1

8

0.00511 negative regulation of behavior

GO:0046008

1

10

0.00511 regulation of female receptivity, post-mating

GO:0045924

1

16

0.00511 regulation of female receptivity

GO:0060180

1

16

0.00511 mating behavior#female mating behavior

GO:0060181

1

16

0.00511 female receptivity

GO:0045297

1

18

0.00511 post-mating behavior

GO:0050795

1

18

0.00511 regulation of behavior

GO:0005179

1

47

0.012

GO:0033057

1

69

0.0139

GO:0032504

1

81

0.0139

GO:0048609

1

81

0.0139

multicellular organism reproduction
multicellular
organism
reproduction#reproductive process in a
multicellular organism

GO:0007617

1

82

0.0139

mating behavior

GO:0051705

1

82

0.0139

behavioral interaction between organisms

GO:0019098

1

87

0.0139

reproductive behavior

GO:0007618

1

94

0.0141

mating

GO:0005102

1

136

0.0193

receptor binding

GO:0022414

1

203

0.0271

reproduction#reproductive process

GO:0051704

1

212

0.0271

multi-organism process

hormone activity
reproductive behavior
organism

in

a

multicellular

Table S5E. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 PostIrradiation at Dose 5000 R. (Analysis with lowest dose discluded.)
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GO

Count Total P Value

GO Name

GO:0007296

1

8

0.0268

GO:0006123

1

14

0.0268

GO:0005751

1

17

0.0268

vitellogenesis
organelle
ATP
synthesis
coupled
electron
transport#mitochondrial electron transport, cytochrome c
to oxygen
mitochondrial inner membrane#mitochondrial respiratory
chain#mitochondrial respiratory chain complex IV

GO:0045277

1

17

0.0268

respiratory chain complex IV

GO:0004129

1

18

0.0268

cytochrome-c oxidase activity

GO:0016675

1

18

0.0268

GO:0016676

1

18

0.0268

oxidoreductase activity, acting on heme group of donors
oxidoreductase activity, acting on heme group of donors,
oxygen as acceptor

GO:0015002

1

18

0.0268

heme-copper terminal oxidase activity

Table S5F. Overrepresented Gene Ontologies in Genes Found to Spike at Day 2 PostIrradiation at Dose 10,000 R. (Analysis with lowest dose discluded.)
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GO

Count Total P Value

GO Name

GO:0007296 4

8

4.14E-10 vitellogenesis

GO:0007292 6

528

1.55E-06 female gamete generation

GO:0003006 4

77

2.64E-06 reproductive developmental process

GO:0007276 6

704

4.37E-06 gamete generation

GO:0019953 6

730

4.37E-06 sexual reproduction

GO:0007028 4

109

5.40E-06 cytoplasm organization and biogenesis

GO:0022414 4

203

5.63E-05 reproduction#reproductive process

GO:0007548 3

57

7.52E-05 sex differentiation

GO:0005737 6

1833 0.000616 cytoplasm

GO:0005811 3

129

0.000708 lipid particle

GO:0048134 2

20

0.000944 germ cell development#germ-line cyst formation

GO:0048477 4

519

0.00136

GO:0016043 5

1962 0.0134

cellular component organization and biogenesis

GO:0044424 6

3454 0.0134

intracellular#intracellular part

GO:0005622 6

3465 0.0134

intracellular

GO:0032502 5

2243 0.0217

developmental process

GO:0008283 2
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0.0222

GO:0007542 1

5

0.0252

cell proliferation
multicellular
organismal
development#germ-line
determination#primary sex determination, germ-line

GO:0019099 1

5

0.0252

female germ-line sex determination

GO:0016590 1

6

0.0278

GO:0018992 1

6

0.0278

ACF complex
multicellular
determination

GO:0007281 2

170

0.0291

GO:0016709 1

7

0.0297

germ cell development
oxidoreductase activity, acting on paired donors, with
incorporation or reduction of molecular oxygen, NADH or
NADPH as one donor, and incorporation of one atom of
oxygen

GO:0008156 1

8

0.0297

negative regulation of DNA replication

GO:0020037 1

8

0.0297

heme binding

GO:0046906 1

8

0.0297

tetrapyrrole binding

GO:0044464 6

4358 0.0297

cell#cell part

GO:0005623 6

4358 0.0297

cell

GO:0051053 1

9

0.0297

negative regulation of DNA metabolic process

GO:0005678 1

9

0.0297

chromatin assembly complex

GO:0006275 1

9

0.0297

regulation of DNA replication

GO:0044444 4

1537 0.0297

cytoplasm#cytoplasmic part

GO:0030237 1

11

multicellular

0.0344

oogenesis
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organismal

organismal

development#germ-line

development#female

sex

sex

sex

determination
GO:0006378 1

12

0.0356

mRNA polyadenylation

GO:0043631 1

12

0.0356

RNA polyadenylation

GO:0045495 1

14

0.0405

pole plasm

GO:0031124 1

16

0.0451

mRNA 3'-end processing

GO:0007280 1

17

0.0457

pole cell migration

GO:0031123 1

17

0.0457

GO:0007538 1

18

0.0472

RNA 3'-end processing
multicellular
organismal
determination

development#primary

sex

Table S5G. Overrepresented Gene Ontologies in Genes Found to Spike at Day 10
Post-Irradiation at Dose 10,000 R. (Analysis with lowest dose discluded.)

(none)
Table S5H. Overrepresented Gene Ontologies in Genes Found to Spike at Day 20
Post-Irradiation at Dose 5000 R. (Analysis with lowest dose discluded.)
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Abstract

Photodynamic therapy is a promising cancer treatment method. However, one possible
limitation is its dependence on light that is not highly penetrating. Copper-Cysteamine
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nanoparticles are a new type of photosensitizer, which generates cytotoxic singlet
oxygen molecules upon activation by x-rays. In this paper, we report the use of
copper cysteamine nanoparticles, targeted to tumors using pH-Low Insertion Peptide.
In an in vivo study, results show significant tumor destruction under x-ray activation.
An analysis of variance shows that mice treated with targeted particles had a
significantly different tumor sizes than mice treated with no particles, as well as mice
treated with non-targeted particles. An additional analysis of variance shows that the
use of targeted copper-cysteamine nanoparticles affected the survival time after
irradiation, compared to irradiation using no particles on mice. This work confirms the
effectiveness of Copper-Cysteamine nanoparticles, targeted to tumors, as a
photosensitizer when activated by radiation therapy. Combined with radiation therapy,
targeted and non-targeted Cu-Cy nanoparticles are good candidates for photodynamic
therapy in deeply seated tumors.

Introduction
Photodynamic therapy (PDT) involves the use of light, a photosensitizer (PS) and
molecular oxygen to kill cells (1-16). Photosensitizers induce the production of
reactive oxygen species (ROS) at the tumor site after the absorption of light energy,
killing the tumor cells. (5, 8, 9, 14, 15, 17, 18). Singlet oxygen has a short lifetime in
biologic systems, less than 0.04 µs, and therefore has a short radius of action of less
than 0.02 µm (17, 19). Photodynamic therapy is safe (2, 10, 12), minimally invasive
and can be used with methods to selectively target cancerous cells, avoiding side
effects to the healthy tissues (1-3, 10-12, 17, 20). Ma et al. successfully used copper
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cysteamine nanoparticles (NPs) activated by microwaves for production of singlet
oxygen to treat cancer using microwave induced photodynamic therapy (21). Copper
sulfide (CuS) nanoparticles excited by 808 nm lasers produced reactive oxygen
species and strong anticancer effects in vitro and in vivo (22). Organically modified
silica (ORMOSIL) nanoparticles (approximately 20 nm) generated cytotoxic singlet
molecules upon photo irradiation after uptake by tumor cells (23). Zinc Oxide (ZnO)
nanoparticles conjugated to porphyrin derivatives showed high phototoxicity in human
ovarian carcinoma cell line when activated with 365 nm UV light, showing a potential
use in photodynamic therapy for deeper cancer treatment (24).
Some advantages of PDT are the available options for photosensitizer and therapeutic
dose, time of irradiation post treatment and light fluence rate (which can be adjusted to
target biological tissues (8)). Although many photosensitizers have been developed,
only a few have shown successful results in vitro and in vivo and made it to clinical
trials(14). One of the drawbacks of PDT is tissue penetration ability because of the
fact that the wavelengths of light for most of the clinically approved photosensitizers
are in the UV/visible range. This limits the use of conventional PDT methods to skin
(surface) tumors only and are not effective for deep tumors (11, 12, 25-28). Another
disadvantage is that the quantum yield of ROS production is lowered under
physiological conditions because photosensitizing drugs have poor solubility in water
and are easily aggregated due to a hydrophobic nature (3, 11, 28). Recently,
nanomaterials combined with photosensitization drugs have been an important method
in

photodynamic

therapy

to

overcome
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the

limitation

of

conventional

photosensitization drugs by increasing the cellular uptake and solubility of drugs in
water (3).
As stated above, one important issue with photodynamic therapy is the tissue depth at
which it can be used as a treatment. One way to address this issue is to use particles
that can interact with more energetic photons. Depending on the source of excitation
energy, nanoparticles can be designed to be excited by near infrared light (NIR),
internal light and X-rays (12). Near infrared light (NIR) can be used to excite
upconversion nanoparticles deep in tissue, with higher penetrating capacity compared
to visible light and low phototoxicity to normal cells and tissues (26, 29). The
upconversion nanoparticles showed a strong photodynamic effect on MB49 cells upon
irradiation with 980 nm near infrared light (30). However, its penetration ability is still
limited compared to X-rays, and it requires high laser light intensity. Further, it is
difficult to design and synthesize because the energy gap of near infrared-absorbing
photosensitizers is narrow, and the quantum yield of singlet oxygen is usually low
(12). Another method for photodynamic therapy is to attach a nanoscintillator to a
photosensitizer. When this is done in vivo and exposed to radiation, the nanoparticles
emit scintillation. This light is absorbed by the photosensitizers, resulting in the
release of singlet oxygen at the tumor site for effective cancer killing. Another
alternative strategy is to use luminescent nanoparticles instead of light sources in vivo
to support photodynamic therapy with more localized therapy and less potential
damage to healthy cells (18, 27). X-rays (0.05 – 6 MeV) have more tissue penetrating
ability than UV/visible/infrared light, which makes it a potential candidate to initiate
photodynamic therapy for deeply seated tumors (12). At present, the use of high
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energy X-rays has been the most common radiation therapy treatment (31). However,
radiation therapy often impacts healthy tissue as well as tumors. If the effect of
radiation on the tumor can be enhanced, less radiation could be used to get the same
effect thus reducing the side effects and damage to the healthy tissues (32). A
combination of conventional radiation therapy with photodynamic therapy has been an
exciting technique for deep tumor penetration (33) and has the potential to result in
lower doses of radiation when scintillation nanoparticles are attached to
photosensitizers (12, 18). The nanoparticles emit light when induced by ionizing
radiation; the scintillation activates the photosensitizers and results in the release of
singlet oxygen. In this case, photodynamic therapy takes place even without the aid of
an external light source, and the effectiveness of the radiation is increased (18). Since
the site of damage from photodynamic therapy depends on the location of the
photosensitizer at the time of irradiation, (20) conjugating the particles with tumor
specific targeting molecules can enhance the uptake of particles with efficient cancer
treatment reducing the damage to the healthy tissues and important organs near the
tumor with the reduced radiation dose (32). X-rays can initiate the photodynamic
agent (LaF3 : Tb3+- meso-tetra ( 4-carbosyphenyl) porphine (MTCP)) scintillating
nanoparticle, even at low dose, for deep cancer treatment (34). The core of a
nanoscintillator coated with a mesoporous silica forms an integrated nanosystem
which when irradiated by X-rays (25). Liu et al. (2008) showed enhanced X-ray
damage by gold nanoparticles treated with a new synthesis method of polyethylene
glycol modification. Trifluorocerium-verteporfin (CeF3 –VP) conjugates, lanthanide
complexes, Copper and cobalt co-doped zinc sulfide (ZnS:Cu,Co) afterglow NPs, and
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nanoscintillator coupled porphyrins have been shown to produce singlet oxygen when
activated by X-ray and are effective for cancer cell destruction (4, 5, 35, 36). Zhang et
al. used a conjugated semiconductor scintillator particle as a photosensitizer with
ionizing radiation, and found diminished oxygen dependence (37). The combined
effect of radiation therapy and photodynamic therapy with indocyanine green as a
sensitizer resulted in killing of MCF7 human breast cancer cells with a reduction in
percentage cell viability, down to 3.42%. A one way ANOVA was used to analyze
data for statistical differences (p < 0.05) (38). When activated by X-rays at 90 kV,
energy was transferred from Ce3+-doped lanthanum(iii) fluoride (LaF3:Ce3+)/DMSO
nanoparticles to protoporphyrin IX (PPIX) with the production of singlet oxygen to
kill cancer cells (39). Porphyrin conjugated with SiC/SiOx nanowires has been an
efficient source of singlet oxygen at low doses of 6MV X-rays (0.4 – 2 Gy), showing
the enhancement of radiation therapy for cancer treatment (40).
In addition to improving upon the depth that photodynamic therapy can reach, another
opportunity for improvement is the use of active targeting agents like peptides,
antibodies and proteins. These agents could reduce the side effects to the surrounding
healthy tissues (3, 41) and problems associated with multidrug resistance (11). There
is a need for more precise photosensitization drug delivery into target cells and tissues
(3), and efforts have been made to search for alternative photodynamic therapy
methods for deep tissue penetration (26, 27). Targeted photodynamic therapy has
been a new promising therapeutic strategy that enhances specificity and efficiency of
photodynamic therapy by improving the delivery of photosensitizers to cancer tissue
(15). Yoon et al. successfully inhibited tumor growth using the hydrophobic
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photosensitizer chlorin e6 (Ce6), conjugated with tumor targeting hyaluronic acid
nanoparticles (HANPs), to generate singlet oxygen in tumor cells when irradiated by
laser. They analyzed the differences between experimental and control groups using a
one-way analysis of variance (ANOVA) and found their results to be considered
statistically significant if p<0.05 (42).
Copper cysteamine nanoparticles (Cu-Cy, Cu3cl(SR)2) are a new option for
photosensitization and radiation therapy. They were used to kill SW620 colorectal
cancer cells by inducing apoptosis as well as autophagy. The difference between the
control and experimental groups was determined using Student’s t test and a one oneway analysis of variance (ANOVA) (43). Copper cysteamine particles under X-ray
activation generated singlet oxygen ( 1O2 ) and were successful at killing MCF-7 cells
both in vitro and in vivo and can be used in the treatment of both shallow and deep
cancers (44, 45). Copper cysteamine has been demonstrated as an X-ray activated
nanoparticle in photodynamic therapy for cancer treatment, which when conjugated by
tumor specific targeting molecules can enhance the uptake (44).
In this paper, we demonstrate the use of copper cysteamine nanoparticles to enhance
radiation therapy, using photodynamic therapy. We targeted copper cysteamine
nanoparticles to tumors using the targeting peptide pH-Low Insertion Peptide
(pHLIP), which targets molecules to tumors using the property that tumors have low
pH. Among many uses, pHLIP has been used to effectively target gold nanoparticles
to tumors and to treat cancer using gold nanoparticles (46-49).

Materials and methods
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Preparation of pHLIP conjugated copper cysteamine nanoparticles
2 mg of Var3 pHLIP (Ala-28-Gly), from CS Bio Company, was added in 5 mL of
deionized water followed by the addition of 3.19 mg of 1 Ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC) under mild stirring for 10 minutes at room
temperature. After adjusting the pH to 7.5 using NaoH, 5 mL of 1 mM copper
cysteamine water solution was added under constant stirring overnight at room
temperature in a dark environment. The copper cysteamine-pHLIP conjugates were
centrifuged at 4400 rpm for 25 minutes and washed with deionized water 3-4 times.
Cell Culture
JC Breast murine cancer cells of BALB/cRos strain were purchased from American
Type Culture Collection (ATCC) and were grown in Roswell Park Memorial Institute
(RPMI) medium with L-glutamine and sodium bicarbonate, 10% Fetal Bovine Serum
(Sigma-Aldrich) and 0.1% Ciprofloxacin. The cells were maintained in a humidified
atmosphere at 5% carbon dioxide at 37 degrees centigrade in an incubator.
Animal Models and Cell Injection
All animal work followed the guidelines of URI IACUC protocol AN1516-003. Males
and Females, 18-25g Balb/c AnNHsd, 3-4 weeks mice were ordered from Envigo.
This strain of mice came to Harlan Sprague Dawley (Hsd-now Envigo) from National
Institutes of Health, Bethesda. The NIH received this strain from Andevont (An). 1.5
million cells suspended in 100uL RPMI were injected subcutaneously on the right
flank of the mice using 1 mL 27 G1/2 latex free BD syringes.
Radiation Therapy on Mice
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Mice were divided into 6 treatment groups: i) targeted copper cysteamine + radiation
ii) untargeted copper cysteamine + radiation iii) PBS (control) + radiation iv) targeted
copper cysteamine v) untargeted copper cysteamine vi) PBS (control). In total, 51
mice (24 males and 27 females) were used for the experiment.
Treatment was undertaken when the tumor size reached approximately 4-8mm. Mice
were anesthetized using isoflurane gas. For groups of mice given nanoparticles, the
particles were injected intratumorally in 20 μL PBS at a particle concentration of 0.8
μg/μL. For the groups given radiation therapy, the mice were irradiated 30 minutes
post injection of particles at an irradiation dose of 5 Gy. No external X-ray filter was
used, and the source to surface distance was set to 30.5 cm with a field size of 18.3 by
20.1 cm. The current and voltage settings of the X-ray machine (a Faxitron MultiRad
350) were 90 kVp and 30 mA. The non-irradiated mice were placed in the x-ray
chamber in the same settings but with no irradiation. The tumor size was measured
daily using digital Vernier calipers (VCD001, from United Scientific Supply) to get
the tumor volume. The tumor volume was calculated using the formula: tumor volume
= ½ length * width2 (50). Mice were euthanized if they reached the endpoint size of 20
mm, or if they showed signs of distress.
Particle characterization
The copper – cysteamine nanoparticles were synthesized in The University of Texas at
Arlington in Wei Chen’s lab along with the singlet oxygen measurement and
photoluminescence and X- ray luminescence measurements (44).
Statistics and Analysis of Data
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In total, 51 mice were used - 24 males and 27 females. Each of the radiation therapy
groups had 3 males and 4 females, whereas the non-RT groups had 5 males and 5
females.
The effect of experimental variables on tumor size in our experiment was quantified
by running an analysis of variance (ANOVA), using the command “anova” in the
statistical computer language R (51). The input given was a linear model (lm
command in R). The independent variable in the linear model was tumor volume, and
the dependent variables were treatment type, time of measurement after irradiation,
age at irradiation, radiation dose (0 or 5 Gy), sex (M or F) and original tumor volume.
Treatment types were run two at a time to generate a comparison between the
following pairs of treatments: i) targeted copper cysteamine particles and untargeted
copper cysteamine particles; ii) targeted copper cysteamine particles and no particles;
iii) untargeted copper cysteamine particles and no particles. p values for individual
variables, as well as interactions of variables were determined using the F test (part of
the anova command in R). p values were ruled significant if the Bonferroni correction
criteria was met. Including interactions, 59 p values were found for each pairwise
comparison of treatment types. We used 0.05/59 = 0.000847 as the cutoff P value for
statistical significance.

Results
Tumor Size Data and Analysis of Variance
Figures 1A and 1B show tumor volume versus time, for male mice (fig. 1) and female
mice (fig. 2) after the intra-tumoral injection of targeted (CuCyP), untargeted (CuCy)
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or no particles (PBS) followed by irradiation with 5 Gray after 30 minutes. In these
figures, each individual curve represents one mouse. Figures 2A (males) and 2B
(females) show tumor volume as a function of time for mice given targeted particles
and either 0 or 5 Gray of radiation. Figures 3A (males) and 3B (females) show tumor
volume growth as a function of time post different treatments either at 0 or 5 Gray
radiation. Supplemental figures 1A, 1B, 2A and 2B show tumor volume as a function
of time for mice given non-targeted particles and no particles.

An analysis of variance (ANOVA) was performed to compare the effects of (targeted
copper cysteamine particles + radiation) with the effects of (non-targeted copper
cysteamine particles + radiation). As described in detail in the methods section, the
dependent variable of the analysis was tumor size and the independent variables were
time after irradiation, sex (male or female), radiation dose (0 or 5 Gy), treatment type
(targeted particles or non-targeted particles), age of mouse at irradiation, and volume
of tumor at time of irradiation. Mice with a treatment of no particles were excluded
from this analysis, so that the variable for treatment type would be a 2-factor
comparison of targeted and non-targeted particles.
Table 1 shows the ANOVA results for an analysis where only two treatment types
were included: targeted and non-targeted particles. In this analysis, the p value for
treatment type is significant (less than 0.000847, the Bonferroni cutoff). This indicates
that mice treated with targeted particles had a significantly different tumor size than
mice treated with non-targeted particles, even when other relevant experimental
variables were also considered.
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In addition to treatment type, the p values for the following variables were also
significant: time after irradiation, radiation dose, treatment type, age of mouse at
irradiation, volume of tumor at time of irradiation. The p value for sex of the mice
shows that sex does not play an important role in the experimental outcome. Several
interaction terms were also significant in the analysis of variance. Of particular note
are: the interactions between time after irradiation and radiation dose (p value <
2.2*10-16), radiation dose and treatment type (p < 5.02*10-9), time after irradiation and
age at irradiation (p<2.2*10-16), treatment type and age at irradiation (p< 3.576*10-11),
time after irradiation and tumor volume at irradiation (p< 6.739*10-10), age at
irradiation and tumor volume at irradiation (p<0.000219). See supplemental table 1
for full information on interaction terms for this analysis.

Table 2 shows the ANOVA results when the following treatment types were included:
non-targeted particles and no particles. In this analysis, all experimental variables
tested had a significant effect on tumor size, including sex. Notable significant
interaction terms included: time after irradiation and radiation dose (p<2.2*10-16), time
after irradiation and age at irradiation (p<2.2*10-16), radiation dose and age at
irradiation (p<2.308*10-13), time after irradiation and tumor volume at irradiation (p<
2.2*10-16), radiation dose and tumor volume at irradiation (p< 6.238*10-6), treatment
type and tumor volume at irradiation (p<1.001*10-6), age at irradiation and tumor
volume at irradiation (p<0.0029175). See supplemental table 2 for full information on
interaction terms for this analysis.
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Table 3 shows the analysis of variance when the following treatment types were
included: targeted particles and no particles. Similar to table 1, all experimental
variables included were significant except sex. Notable significant interaction terms
included: time after irradiation and sex (p<5.753*10-5), time after irradiation and
radiation dose (p<2.2*10-16), radiation dose and treatment type (p<1.15*10-8), time
after irradiation and age at irradiation (p<2.2*10-16), treatment type and age at
irradiation (p<1.243*10-10), time after irradiation and tumor volume at irradiation
(p<2.2*10-16), radiation dose and tumor volume at irradiation (p<0.002), age at
irradiation and tumor volume at irradiation (p<0.003374). See supplemental table 3 for
full information on interaction terms for this analysis.

ANOVA Analysis of Survival
The number of mice used in this experiment was insufficient to run an effective log
rank test for differences between survival curves. As a substitute analysis, an analysis
of variance was run with time between irradiation and death as the dependent variable.
(Here, death is defined as either actual death or as reaching a humane endpoint
following our institution’s IACUC policies.) The independent variables were sex (M
or F), radiation dose (0 or 5 Gy), treatment type (targeted particles, non-targeted
particles, no particles), age of mouse at time of irradiation, and size of the mouse’s
tumor at time of irradiation. Including interaction terms, there were 29 variable
combinations assessed for significance; we used a Bonferroni cutoff p value of 0.05/29
= 0.00172 to claim significance.
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A comparison using mice treated with targeted particles or no particles found a
statistically significant effect from treatment (targeted particles versus no particles),
sex and radiation dose. Thus, the anova analysis indicates that targeted particles
increase survival time, compared to irradiation using no particles. Notable interaction
terms that were significant included radiation dose with treatment type, and radiation
dose with tumor size at time of irradiation. The input and output of this analysis is
supplemental tables 4 and 5. Analyses run with the other combinations of treatments
(targeted particles versus non-targeted particles, non-targeted particles versus no
particles) found no significant effects from the treatment differences.

Discussion
In this paper, we demonstrated that copper cysteamine nanoparticles, targeted with
pH-Low Insertion Peptide, can be used to reduce tumor size and to increase survival in
mammals. Copper cysteamine can be used in the treatment of both shallow and deep
tumors because it can be activated by X-rays as well as light (44). In this result, we
particularly emphasize the effect on tumor size.
The targeted Copper cysteamine particles showed the enhanced radiation effect with
better tumor killing in both the male and female mice. The sex of the mice might not
be an important variable in this kind of experiment as this parameter was not
statistically significant in targeted vs non tartgeted and targeted versus no particles.
However for nontargeted versus no particles it played an important role. The original
volume of tumor and age factor of mice at irradiation time are also very important to
be considered while performing the experiment. The dose of the radiation given to the
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mice could be altered to see the affect in the tumor size as the radiation dose is
statistically significant.
One particularly important variable that was not tested in this paper is radiation
energy. Few, if any, photoluminescent particles have been shown to work at energies
as high as 90 kVp, as shown in this paper. However, most clinically relevant energies
are higher still.
Overall, this paper represents a firm demonstration of the effectiveness of coppercysteamine nanoparticles in the treatment of mammalian cancer.
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Tables:
Table 1. Analysis of variance results, comparing treatment with targeted copper
cysteamine particles to treatment with non-targeted particles.

pHLIP Targeted Copper Cysteamine Particles Vs Non-targeted Copper Cysteamine
Particles
Variable

p Value

Time After Irradiation (Days)

< 2.2*10-16

Sex

< 0.9968

Radiation Dose (Gray)

< 2.2*10-16

Treatment Type

< 0.0006079

Age of Mouse at Irradiation (Days)

< 2.2*10-12

Volume of Tumor at Irradiation (mm3)

< 2.2*10-10
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Table 2. Analysis of variance results, comparing treatment with non-targeted copper
cysteamine particles to treatment with no particles.

Non-targeted Copper Cysteamine Particles Vs No Particles
Variable

pValues

Day after irradiation(days)

< 2.2*10-16

Sex

< 0.0001556

Radiation Dose (Gray)

< 2.2*10-16

Treatment Type

< 2.467*10-7

Age at irradiation (Days)

< 2.2*10-16

Original Tumor Volume(mm3)

< 2.2*10-16

Table 3. Analysis of variance results, comparing treatment with targeted copper
cysteamine particles to treatment with no particles.

pHLIP Targeted Copper Cysteamine Vs No Particles
Variable

pValues

Day after irradiation(days)

< 2.2*10-16

Sex

< 0.282

Radiation Dose (Gray)

< 2.2*10-16

Treatment Type

< 2.49*10-19

Age at irradiation (Days)

< 4.11*10-13

Original Tumor Volume(mm3)

< 2.2*10-16
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Figures:

Days after irradiation Vs tumor size for different
treatment types in male mice
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Figure 1A
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Days after irradiation Vs tumor size for different
treatment types in female mice
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Figure 1. Tumor size as a function of time, for mice given 5 Gray of radiation. Each
individual curve represents one mouse. CuCyP mice were given a targeted coppercysteamine treatment; CuCy mice were given a non-targeted copper-cysteamine
treatment; PBS mice were injected with a control solution containing no particles.
Figure A is male mice; figure B is female mice.
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Days after treatment Vs tumor size for irradiated
and unirradiated targeted particles in female mice
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Figure 2. Tumor size as a function of time, for mice given a targeted copper
cysteamine treatment. Each individual curve represents one mouse. Red curves are
mice given 5 Gy of radiation; green curves are mice given 0 Gy of radiation. Figure A
is male mice; figure B is female mice.
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Days after irradiation Vs tumor size for different all
types in male mice
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Figure 3. Tumor size as a function of time, for mice given different treatments. Each
individual curve represents a single treatment either at 5 Gy or at 0 Gy of radiation.
Figure A is male mice; figure B is female mice.
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SUPPLEMENTARY DATA

Supplemental Figures 1A – 2 B

Days after treatment Vs tumor size for irradiated
and unirradiated nontargeted particles in male mice
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Days after treatment Vs tumor size for irradiated
and unirradiated nontargeted particles in female
mice
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Figure S1. Tumor size as a function of time, for mice given a non-targeted copper
cysteamine treatment. Each individual curve represents one mouse. Red curves are
mice given 5 Gy of radiation; green curves are mice given 0 Gy of radiation. Figure A
is male mice; figure B is female mice.
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Days after treatment Vs tumor size for irradiated and
unirradiated noparticles in male mice
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Days after treatment Vs tumor size for irradiated and
unirradiated noparticles in female mice
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Figure S2. Tumor size as a function of time, for mice given a control (no particles)
treatment. Each individual curve represents one mouse. Red curves are mice given 5
Gy of radiation; green curves are mice given 0 Gy of radiation. Figure A is male mice;
figure B is female mice.
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Table S1: Information on interaction terms for targeted and non-targeted
copper-cysteamine

day.after.irradiation

< 2.2e-16

sex

0.9968423

radiation.dose.Gy.

< 2.2e-16

treatment.type

0.0006079

age.at.irradiation.days.

1.07E-12

Original.tumor.volume

< 2.2e-16

day.after.irradiation:sex

0.0052499

day.after.irradiation:radiation.dose.Gy.

< 2.2e-16

sex:radiation.dose.Gy.

0.2877592

day.after.irradiation:treatment.type

0.2422588

sex:treatment.type

0.925823

radiation.dose.Gy.:treatment.type

5.02E-09

day.after.irradiation:age.at.irradiation.days.

< 2.2e-16

sex:age.at.irradiation.days.

0.0581423

radiation.dose.Gy.:age.at.irradiation.days.

0.0741023

treatment.type:age.at.irradiation.days.

3.58E-11

day.after.irradiation:Original.tumor.volume

6.74E-16

sex:Original.tumor.volume

0.0893735

radiation.dose.Gy.:Original.tumor.volume

0.3569157

treatment.type:Original.tumor.volume

0.3732059

age.at.irradiation.days.:Original.tumor.volume

0.000219

day.after.irradiation:sex:radiation.dose.Gy.

0.0002324
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day.after.irradiation:sex:treatment.type

0.0642263

day.after.irradiation:radiation.dose.Gy.:treatment.type

2.48E-09

sex:radiation.dose.Gy.:treatment.type

0.4166221

day.after.irradiation:sex:age.at.irradiation.days.

0.002378

day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.

0.709861

sex:radiation.dose.Gy.:age.at.irradiation.days.

0.0825586

day.after.irradiation:treatment.type:age.at.irradiation.days.

0.690005

sex:treatment.type:age.at.irradiation.days.

1.10E-06

radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

1.54E-10

day.after.irradiation:sex:Original.tumor.volume

0.0023348

day.after.irradiation:radiation.dose.Gy.:Original.tumor.volume

0.0098703

sex:radiation.dose.Gy.:Original.tumor.volume

0.9326714

day.after.irradiation:treatment.type:Original.tumor.volume

0.0147587

sex:treatment.type:Original.tumor.volume

0.1858568

radiation.dose.Gy.:treatment.type:Original.tumor.volume

0.0021191

day.after.irradiation:age.at.irradiation.days.:Original.tumor.volume

4.63E-06

sex:age.at.irradiation.days.:Original.tumor.volume

0.0001083

radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volume

0.914267

treatment.type:age.at.irradiation.days.:Original.tumor.volume

2.10E-15

day.after.irradiation:sex:radiation.dose.Gy.:treatment.type

0.1826445

day.after.irradiation:sex:radiation.dose.Gy.:age.at.irradiation.days.

0.0002631

day.after.irradiation:sex:treatment.type:age.at.irradiation.days.

0.0017918

day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

1.41E-10

sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

0.0015014

day.after.irradiation:sex:radiation.dose.Gy.:Original.tumor.volume

0.0008715

day.after.irradiation:sex:treatment.type:Original.tumor.volume

1.16E-11

day.after.irradiation:radiation.dose.Gy.:treatment.type:Original.tumor.volume

0.7065459
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sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume

< 2.2e-16

day.after.irradiation:sex:age.at.irradiation.days.:Original.tumor.volume

0.8580931

day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volume

5.60E-06

day.after.irradiation:treatment.type:age.at.irradiation.days.:Original.tumor.volume

0.0001225

sex:treatment.type:age.at.irradiation.days.:Original.tumor.volume

0.8950907

radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Original.tumor.volume

1.82E-09

day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

1.67E-05

day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume

< 2.2e-16

day.after.irradiation:sex:treatment.type:age.at.irradiation.days.:Original.tumor.volume

0.0282005

day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Original.t

0.1153768

umor.volume
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Table S2: Information on interaction terms for non-targeted copper-cysteamine
and no particles

day.after.irradiation

< 2.2e-16

sex

0.0001556

radiation.dose.Gy.

< 2.2e-16

treatment.type

2.47E-07

age.at.irradiation.days.

< 2.2e-16

Original.tumor.volume

< 2.2e-16

day.after.irradiation:sex

0.0137652

day.after.irradiation:radiation.dose.Gy.

< 2.2e-16

sex:radiation.dose.Gy.

0.8973791

day.after.irradiation:treatment.type

0.0412466

sex:treatment.type

0.4474246

radiation.dose.Gy.:treatment.type

0.2525226

day.after.irradiation:age.at.irradiation.days.

< 2.2e-16

sex:age.at.irradiation.days.

0.5539768

radiation.dose.Gy.:age.at.irradiation.days.

2.31E-13

treatment.type:age.at.irradiation.days.

0.0036885

day.after.irradiation:Original.tumor.volume

< 2.2e-16

sex:Original.tumor.volume

0.0793622

radiation.dose.Gy.:Original.tumor.volume

6.24E-06

treatment.type:Original.tumor.volume

1.00E-06

age.at.irradiation.days.:Original.tumor.volume

0.0029175

day.after.irradiation:sex:radiation.dose.Gy.

0.6529036

day.after.irradiation:sex:treatment.type

0.4082707

day.after.irradiation:radiation.dose.Gy.:treatment.type

0.0155393

sex:radiation.dose.Gy.:treatment.type

0.0153287

day.after.irradiation:sex:age.at.irradiation.days.

0.3772449

day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.

1.73E-06

sex:radiation.dose.Gy.:age.at.irradiation.days.

5.69E-06

day.after.irradiation:treatment.type:age.at.irradiation.days.

0.4607212

sex:treatment.type:age.at.irradiation.days.

0.1209064

radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

< 2.2e-16

day.after.irradiation:sex:Original.tumor.volume

0.9639791

day.after.irradiation:radiation.dose.Gy.:Original.tumor.volume

0.0003828

sex:radiation.dose.Gy.:Original.tumor.volume

0.2379018
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day.after.irradiation:treatment.type:Original.tumor.volume

0.0007917

sex:treatment.type:Original.tumor.volume

9.74E-10

radiation.dose.Gy.:treatment.type:Original.tumor.volume

0.710651

day.after.irradiation:age.at.irradiation.days.:Original.tumor.volume

0.2090692

sex:age.at.irradiation.days.:Original.tumor.volume

1.78E-12

radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volume

1.06E-05

treatment.type:age.at.irradiation.days.:Original.tumor.volume

0.2889579

day.after.irradiation:sex:radiation.dose.Gy.:treatment.type

0.1049055

day.after.irradiation:sex:radiation.dose.Gy.:age.at.irradiation.days.

0.0222449

day.after.irradiation:sex:treatment.type:age.at.irradiation.days.

0.0038017

day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

< 2.2e-16

sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

0.0013554

day.after.irradiation:sex:radiation.dose.Gy.:Original.tumor.volume

4.04E-11

day.after.irradiation:sex:treatment.type:Original.tumor.volume

2.50E-14

day.after.irradiation:radiation.dose.Gy.:treatment.type:Original.tumor.volume

3.51E-06

sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume

0.0003807

day.after.irradiation:sex:age.at.irradiation.days.:Original.tumor.volume

6.10E-13

day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volum
e
day.after.irradiation:treatment.type:age.at.irradiation.days.:Original.tumor.volume

1.42E-09

sex:treatment.type:age.at.irradiation.days.:Original.tumor.volume

0.0119215

radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Original.tumor.volume

< 2.2e-16

day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

0.0005915

day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume

0.2044633

day.after.irradiation:sex:treatment.type:age.at.irradiation.days.:Original.tumor.volum
e
day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Origin
al.tumor.volume

3.34E-08
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1.40E-07

2.23E-09

Table S3: Information on interaction terms for targeted copper-cysteamine
particles and no particles

day.after.irradiation

< 2.2e-16

sex

0.282695

radiation.dose.Gy.

< 2.2e-16

treatment.type

2.49E-14

age.at.irradiation.days.

4.11E-13

Original.tumor.volume

< 2.2e-16

day.after.irradiation:sex

5.75E-05

day.after.irradiation:radiation.dose.Gy.

< 2.2e-16

sex:radiation.dose.Gy.

0.554205

day.after.irradiation:treatment.type

0.002546

sex:treatment.type

0.422989

radiation.dose.Gy.:treatment.type

1.15E-08

day.after.irradiation:age.at.irradiation.days.

< 2.2e-16

sex:age.at.irradiation.days.

0.303295

radiation.dose.Gy.:age.at.irradiation.days.

0.66228

treatment.type:age.at.irradiation.days.

1.24E-10

day.after.irradiation:Original.tumor.volume

< 2.2e-16

sex:Original.tumor.volume

0.0287

radiation.dose.Gy.:Original.tumor.volume

0.002048

treatment.type:Original.tumor.volume

0.880755

age.at.irradiation.days.:Original.tumor.volume

0.003374

day.after.irradiation:sex:radiation.dose.Gy.

0.103475

day.after.irradiation:sex:treatment.type

0.82539

day.after.irradiation:radiation.dose.Gy.:treatment.type

1.84E-10

sex:radiation.dose.Gy.:treatment.type

0.652948

day.after.irradiation:sex:age.at.irradiation.days.

4.55E-05

day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.

0.069363

sex:radiation.dose.Gy.:age.at.irradiation.days.

0.399175

day.after.irradiation:treatment.type:age.at.irradiation.days.

0.025123

sex:treatment.type:age.at.irradiation.days.

0.003863

radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

< 2.2e-16

day.after.irradiation:sex:Original.tumor.volume

0.012177

day.after.irradiation:radiation.dose.Gy.:Original.tumor.volume

0.538656

sex:radiation.dose.Gy.:Original.tumor.volume

< 2.2e-16
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day.after.irradiation:treatment.type:Original.tumor.volume

2.31E-06

sex:treatment.type:Original.tumor.volume

0.302969

radiation.dose.Gy.:treatment.type:Original.tumor.volume

< 2.2e-16

day.after.irradiation:age.at.irradiation.days.:Original.tumor.volume

0.337459

sex:age.at.irradiation.days.:Original.tumor.volume

0.265691

radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.volume

1.31E-05

treatment.type:age.at.irradiation.days.:Original.tumor.volume

0.653384

day.after.irradiation:sex:radiation.dose.Gy.:treatment.type

2.43E-05

day.after.irradiation:sex:radiation.dose.Gy.:age.at.irradiation.days.

3.60E-11

day.after.irradiation:sex:treatment.type:age.at.irradiation.days.

6.86E-05

day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

< 2.2e-16

sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.

7.71E-07

day.after.irradiation:sex:radiation.dose.Gy.:Original.tumor.volume

< 2.2e-16

day.after.irradiation:sex:treatment.type:Original.tumor.volume

0.061314

day.after.irradiation:radiation.dose.Gy.:treatment.type:Original.tumor.volume

4.88E-10

sex:radiation.dose.Gy.:treatment.type:Original.tumor.volume

5.73E-06

day.after.irradiation:sex:age.at.irradiation.days.:Original.tumor.volume

0.612714

day.after.irradiation:radiation.dose.Gy.:age.at.irradiation.days.:Original.tumor.vo
lume
day.after.irradiation:treatment.type:age.at.irradiation.days.:Original.tumor.volu
me
sex:treatment.type:age.at.irradiation.days.:Original.tumor.volume

1.64E-09

radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:Original.tumor.volum
e
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:age.at.irradiation.day
s.
day.after.irradiation:sex:radiation.dose.Gy.:treatment.type:Original.tumor.volum
e
day.after.irradiation:sex:treatment.type:age.at.irradiation.days.:Original.tumor.v
olume
day.after.irradiation:radiation.dose.Gy.:treatment.type:age.at.irradiation.days.:O
riginal.tumor.volume

0.008293
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8.51E-07
0.15134

0.024138
0.00421
0.35164
5.02E-07

Table S4: Survival Experiment Data

Mouse
Number

222

Days
between
Irradiation
and death
93

Sex

Irradiatio
n
Dose
(Gy)
5

Treatment
Type

Age at
Irradiatio
n (days)
CuCyP

59

Size of
tumor
on day of
irradiation
49.36

5

CuCyP

66

68.26

M
234

64
M

251

74

5

CuCyP

66

80.76

5

CuCyP

48

75.16

229

66

M
F

239

65

F

5

CuCyP

94

78.14

280

79

F

5

CuCyP

90

82.86

282

10
3
70

F

5

CuCyP

96

57.24

5

CuCy

59

64.71

5

CuCy

66

54.05

225

M
235

66
M

253

68

5

CuCy

66

71.35

5

CuCy

83

61.58

250

68

M
F

240

73

F

5

CuCy

59

63.01

281

29

F

5

CuCy

90

139.66

283

82

F

5

CuCy

96

72.15

226

19

5

No Particles

59

66.13

5

No Particles

66

57.74

M
237

17
M

252

73

5

No Particles

66

61.9

5

No Particles

83

52.65

232

91

M
F

236

64

F

5

No Particles

52

50.66

254

48

F

5

No Particles

66

58.16

284

49

F

5

No Particles

117

104.97

223

39

0

CuCyP

59

76.46

0

CuCyP

73

65.59

0

CuCyP

76

72.04

M
243

57
M

247

26
M

347

24

228

40

M
F

241

51

F

0

CuCyP

67

68.36

0

CuCyP

83

64.09

0

CuCyP

59

73

162

278

25

F

0

CuCyP

100

83.48

296

38

F

0

CuCyP

125

134.57

348

34

F

0

CuCyP

67

107.4

224

65

0

CuCy

59

96

0

CuCy

59

96

0

CuCy

76

70.63

0

CuCy

80

68.88

M
244

44
M

248

39
M

264

44
M

355

35

0

CuCy

90

93.88

0

CuCy

48

75.57

230

62

M
F

242

57

F

0

CuCy

59

60.15

279

29

F

0

CuCy

100

78.42

297

25

F

0

CuCy

125

173.94

350

41

F

0

CuCy

75

64.85

227

39

0

No Particles

59

41.65

0

No Particles

59

174.44

0

No Particles

76

81.57

0

No Particles

49

62.53

M
245

40
M

249

28
M

335

39
M

356

28

0

No Particles

48

62.72

0

No Particles

52

91.39

238

49

M
F

258

45

F

0

No Particles

52

93.95

344

37

F

0

No Particles

59

83.15

345

28

F

0

No Particles

59

77.13
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Table S5 Analysis of Variance Results on Survival Data

data$sex

0.0013965

data$radiation_dose.Gy.

8.55E-05

data$treatment_type

0.0016282

data$age_at_irradiation.days.

0.0066644

data$size_of_tumor_on_day_of_irradiation

0.0400424

data$sex:data$radiation_dose.Gy.

0.0072156

data$sex:data$treatment_type

0.0095929

data$radiation_dose.Gy.:data$treatment_type

0.0005156

data$sex:data$age_at_irradiation.days.

0.018785

data$radiation_dose.Gy.:data$age_at_irradiation.days.

0.0426896

data$treatment_type:data$age_at_irradiation.days.

0.123847

data$sex:data$size_of_tumor_on_day_of_irradiation

0.0038603

data$radiation_dose.Gy.:data$size_of_tumor_on_day_of_irradiation

0.0008749

data$treatment_type:data$size_of_tumor_on_day_of_irradiation

0.0410717

data$age_at_irradiation.days.:data$size_of_tumor_on_day_of_irradiation

0.0049635

data$sex:data$radiation_dose.Gy.:data$treatment_type

0.0599268

data$sex:data$radiation_dose.Gy.:data$age_at_irradiation.days.

0.0598588

data$sex:data$treatment_type:data$age_at_irradiation.days.

0.1531105

data$radiation_dose.Gy.:data$treatment_type:data$age_at_irradiation.days.

0.0024378

data$sex:data$radiation_dose.Gy.:data$size_of_tumor_on_day_of_irradiation

0.0047904

data$sex:data$treatment_type:data$size_of_tumor_on_day_of_irradiation

0.0026771

data$radiation_dose.Gy.:data$treatment_type
:data$size_of_tumor_on_day_of_irradiation

0.0397707

data$sex:data$age_at_irradiation.days
.:data$size_of_tumor_on_day_of_irradiation

0.1807822

data$radiation_dose.Gy.:data$age_at_irradiation.days
.:data$size_of_tumor_on_day_of_irradiation

0.0224007
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data$treatment_type:data$age_at_irradiation.days
.:data$size_of_tumor_on_day_of_irradiation

0.0023849

data$sex:data$radiation_dose.Gy.:data$treatment_type
:data$age_at_irradiation.days.

0.0060847

data$sex:data$radiation_dose.Gy.:data$treatment_type
:data$size_of_tumor_on_day_of_irradiation

0.0006902

data$sex:data$treatment_type:data$age_at_irradiation.days
.:data$size_of_tumor_on_day_of_irradiation

0.0283519

data$radiation_dose.Gy.:data$treatment_type:data$age_at_irradiation.days
.:data$size_of_tumor_on_day_of_irradiation

0.0291779

165

